349 lines
238 KiB
Text
349 lines
238 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK65849">
|
|
<meta name="ncbi_domain" content="pdqcis">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK65849/?report=reader">
|
|
<meta name="ncbi_pagename" content="Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="PDQ Cancer Information Summaries [Internet]">
|
|
<meta name="citation_title" content="Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)">
|
|
<meta name="citation_publisher" content="National Cancer Institute (US)">
|
|
<meta name="citation_date" content="2024/08/16">
|
|
<meta name="citation_author" content="PDQ Adult Treatment Editorial Board">
|
|
<meta name="citation_pmid" content="26389288">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK65849/">
|
|
<meta name="citation_keywords" content="mycosis fungoides/Sezary syndrome">
|
|
<meta name="citation_keywords" content="mycosis fungoides and other cutaneous T-cell lymphomas">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Cancer Institute (US)">
|
|
<meta name="DC.Contributor" content="PDQ Adult Treatment Editorial Board">
|
|
<meta name="DC.Date" content="2024/08/16">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK65849/">
|
|
<meta name="description" content="Mycosis fungoides and other cutaneous T-cell lymphomas are neoplasias of malignant T lymphocytes that affect the skin. Learn about the clinical presentation, prognosis, staging, and treatment for mycosis fungoides and other cutaneous T-cell lymphomas in this expert-reviewed summary.">
|
|
<meta name="og:title" content="Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Mycosis fungoides and other cutaneous T-cell lymphomas are neoplasias of malignant T lymphocytes that affect the skin. Learn about the clinical presentation, prognosis, staging, and treatment for mycosis fungoides and other cutaneous T-cell lymphomas in this expert-reviewed summary.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK65849/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/pdqcis/CDR0000062881/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK65849/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E5D7B7C9507F10000000000E100BA.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK65849/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"></div><div class="body"><div class="t">Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®): Health Professional Version</div><div class="j">PDQ Cancer Information Summaries [Internet]</div></div><div class="tail"></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK65849/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK65849/&text=Mycosis%20Fungoides%20and%20Other%20Cutaneous%20T-Cell%20Lymphomas%20Treatment%20(PDQ%AE)"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/pdqcis/?report=reader">Title Information</a><a href="/books/n/pdqcis/toc/?report=reader">Table of Contents Page</a><a href="#_NBK65849_">Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®): Health Professional Version</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK65849/?report=classic">Switch to classic view</a><a href="/books/NBK65849/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK65849%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E5D7B7C9507F10000000000E100BA.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK65849_"><span class="title" itemprop="name">Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)</span></h1><div class="subtitle whole_rhythm">Health Professional Version</div><p class="contribs">PDQ Adult Treatment Editorial Board.</p><p class="fm-aai"><a href="#_NBK65849_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p id="CDR0000062881__297">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of mycosis fungoides and other cutaneous T-cell lymphomas. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</p><p id="CDR0000062881__298">This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p></div><div id="CDR0000062881__1"><h2 id="_CDR0000062881__1_">General Information About Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas </h2><div id="CDR0000062881__287"><h3>Clinical Presentation</h3><p id="CDR0000062881__3">Cutaneous T-cell lymphomas, which include mycosis fungoides and Sézary syndrome, are neoplasias of malignant
|
|
T lymphocytes that usually possess the helper/inducer cell surface phenotype and initially present as skin involvement.[<a class="bibr" href="#CDR0000062881_rl_1_1" rid="CDR0000062881_rl_1_1">1</a>] Cutaneous T-cell lymphomas should be distinguished from other T-cell lymphomas that
|
|
involve the skin, such as anaplastic large cell lymphoma (CD30 positive),
|
|
peripheral T-cell lymphoma (CD30 negative, with no epidermal involvement),
|
|
or adult T-cell leukemia/lymphoma (usually with systemic involvement).[<a class="bibr" href="#CDR0000062881_rl_1_2" rid="CDR0000062881_rl_1_2">2</a>,<a class="bibr" href="#CDR0000062881_rl_1_3" rid="CDR0000062881_rl_1_3">3</a>] For more information about these types of T-cell lymphomas, see <a href="/books/n/pdqcis/CDR0000811763/?report=reader">Peripheral T-Cell Non-Hodgkin Lymphoma Treatment</a>.
|
|
</p><p id="CDR0000062881__369">Typically, the natural history of cutaneous T-cell lymphoma is indolent.[<a class="bibr" href="#CDR0000062881_rl_1_4" rid="CDR0000062881_rl_1_4">4</a>] Symptoms of the disease
|
|
may be present for long periods, in a range of 2 to 10 years, because cutaneous eruptions wax and wane
|
|
before being confirmed by biopsy. Cutaneous T-cell lymphomas are treatable with
|
|
available topical therapy, systemic therapy, or both. Curative modalities have
|
|
proven elusive, with the possible exception of patients with minimal
|
|
disease confined to the skin.
|
|
</p><p id="CDR0000062881__370">In
|
|
addition, several benign or indolent conditions can be confused with
|
|
mycosis fungoides. It is important to consult with a pathologist who has
|
|
expertise in distinguishing these conditions.[<a class="bibr" href="#CDR0000062881_rl_1_1" rid="CDR0000062881_rl_1_1">1</a>]
|
|
</p></div><div id="CDR0000062881__286"><h3>Prognosis and Survival</h3><p id="CDR0000062881__563">The prognosis of patients with cutaneous T-cell lymphomas is based on the extent of disease (stage) at
|
|
presentation.[<a class="bibr" href="#CDR0000062881_rl_1_5" rid="CDR0000062881_rl_1_5">5</a>] The presence of lymphadenopathy and involvement of
|
|
peripheral blood and viscera increase in likelihood with worsening cutaneous
|
|
involvement and define poor prognostic groups.[<a class="bibr" href="#CDR0000062881_rl_1_5" rid="CDR0000062881_rl_1_5">5</a>-<a class="bibr" href="#CDR0000062881_rl_1_8" rid="CDR0000062881_rl_1_8">8</a>] The Cutaneous Lymphoma International Consortium retrospectively reviewed 1,275 patients and found that the following four independent prognostic markers indicate a worse survival:[<a class="bibr" href="#CDR0000062881_rl_1_9" rid="CDR0000062881_rl_1_9">9</a>]</p><ul id="CDR0000062881__545"><li class="half_rhythm"><div>Stage IV disease.</div></li><li class="half_rhythm"><div>Age older than 60 years.</div></li><li class="half_rhythm"><div>Large cell transformation.</div></li><li class="half_rhythm"><div>Elevated lactate dehydrogenase.</div></li></ul><p id="CDR0000062881__4"> The median survival
|
|
following diagnosis varies according to stage. Patients with stage IA disease
|
|
have a median survival of 20 years or more. Most deaths for this
|
|
group are not caused by, nor are they related to, mycosis fungoides.[<a class="bibr" href="#CDR0000062881_rl_1_10" rid="CDR0000062881_rl_1_10">10</a>,<a class="bibr" href="#CDR0000062881_rl_1_11" rid="CDR0000062881_rl_1_11">11</a>] In contrast, more
|
|
than 50% of patients with stage III through stage IV disease die of mycosis fungoides, with a
|
|
median survival of approximately 5 years.[<a class="bibr" href="#CDR0000062881_rl_1_7" rid="CDR0000062881_rl_1_7">7</a>,<a class="bibr" href="#CDR0000062881_rl_1_9" rid="CDR0000062881_rl_1_9">9</a>,<a class="bibr" href="#CDR0000062881_rl_1_12" rid="CDR0000062881_rl_1_12">12</a>,<a class="bibr" href="#CDR0000062881_rl_1_13" rid="CDR0000062881_rl_1_13">13</a>] The Cutaneous Lymphoma International Prognostic index used male sex, age older than 60 years, plaques, lymph nodes, blood involvement, and visceral involvement as poor prognostic factors to define predicted overall survival (OS) and progression-free survival in both early-stage and advanced-stage groups.[<a class="bibr" href="#CDR0000062881_rl_1_14" rid="CDR0000062881_rl_1_14">14</a>]
|
|
</p><p id="CDR0000062881__372">A report on 1,798 patients from the <a href="https://seer.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program</a> database found an increase in second malignancies in patients with mycosis fungoides (standardized incidence ratio, 1.32; 95% confidence interval [CI], 1.15–1.52), especially for Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma.[<a class="bibr" href="#CDR0000062881_rl_1_15" rid="CDR0000062881_rl_1_15">15</a>] Another report on 4,459 patients from the SEER database found that the 19.2% of African American patients with mycosis fungoides had shorter OS, potentially attributable to disease characteristics, socioeconomic status, and type of therapy (hazard ratio, 1.47; 95% CI, 1.25–1.74; <i>P</i> < .001).[<a class="bibr" href="#CDR0000062881_rl_1_16" rid="CDR0000062881_rl_1_16">16</a>]</p><p id="CDR0000062881__6">Cutaneous disease can manifest as an eczematous patch or plaque stage
|
|
covering less than 10% of the body surface (T1), a plaque stage covering
|
|
10% or more of the body surface (T2), or as tumors
|
|
(T3) that frequently undergo necrotic ulceration.[<a class="bibr" href="#CDR0000062881_rl_1_17" rid="CDR0000062881_rl_1_17">17</a>,<a class="bibr" href="#CDR0000062881_rl_1_18" rid="CDR0000062881_rl_1_18">18</a>] Several retrospective studies showed that 20% of patients have disease that progresses from stage I or II to stage III or IV.[<a class="bibr" href="#CDR0000062881_rl_1_19" rid="CDR0000062881_rl_1_19">19</a>-<a class="bibr" href="#CDR0000062881_rl_1_21" rid="CDR0000062881_rl_1_21">21</a>] Sézary syndrome presents with generalized erythroderma (T4) and peripheral blood involvement. However, there is some disagreement about whether mycosis fungoides and Sézary syndrome are actually variants of the same disease.[<a class="bibr" href="#CDR0000062881_rl_1_22" rid="CDR0000062881_rl_1_22">22</a>] The same retrospective study with a median follow-up of 14.5 years found that only 3% of 1,422 patients progressed from mycosis fungoides to Sézary syndrome.[<a class="bibr" href="#CDR0000062881_rl_1_19" rid="CDR0000062881_rl_1_19">19</a>]
|
|
</p><p id="CDR0000062881__373"> There is consensus that patients with Sézary syndrome (leukemic involvement) have a poor prognosis (median survival, 4 years), with or without the typical generalized erythroderma.[<a class="bibr" href="#CDR0000062881_rl_1_23" rid="CDR0000062881_rl_1_23">23</a>,<a class="bibr" href="#CDR0000062881_rl_1_24" rid="CDR0000062881_rl_1_24">24</a>] Cytologic transformation from a low-grade lymphoma to a high-grade
|
|
lymphoma (large cell transformation) occurs rarely (<5%) during the course of these diseases and is associated
|
|
with a poor prognosis.[<a class="bibr" href="#CDR0000062881_rl_1_25" rid="CDR0000062881_rl_1_25">25</a>-<a class="bibr" href="#CDR0000062881_rl_1_27" rid="CDR0000062881_rl_1_27">27</a>] A retrospective analysis of 100 cases with large cell transformation found reduced disease-specific survival with extracutaneous transformation, increased extent of skin lesions, and CD30 negativity.[<a class="bibr" href="#CDR0000062881_rl_1_28" rid="CDR0000062881_rl_1_28">28</a>] A common cause of death during the tumor phase is
|
|
septicemia caused by chronic skin
|
|
infection with staph species, herpes simplex, herpes zoster, and fungal skin infections.[<a class="bibr" href="#CDR0000062881_rl_1_29" rid="CDR0000062881_rl_1_29">29</a>,<a class="bibr" href="#CDR0000062881_rl_1_30" rid="CDR0000062881_rl_1_30">30</a>]</p><p id="CDR0000062881__568">Folliculotropic mycosis fungoides is a variant of mycosis fungoides marked by folliculotropic, rather than epidermotropic, neoplastic infiltrates, with preferential location in the head and neck area.[<a class="bibr" href="#CDR0000062881_rl_1_31" rid="CDR0000062881_rl_1_31">31</a>] Early plaque-stage folliculotropic mycosis fungoides have a very indolent prognosis, while extracutaneous disease portends a very poor prognosis.[<a class="bibr" href="#CDR0000062881_rl_1_31" rid="CDR0000062881_rl_1_31">31</a>]</p></div><div id="CDR0000062881_rl_1"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062881_rl_1_1">Wilcox RA: Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 92 (10): 1085-1102, 2017. [<a href="https://pubmed.ncbi.nlm.nih.gov/28872191" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28872191</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_2">Willemze R, Kerl H, Sterry W, et al.: EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90 (1): 354-71, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9207472" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9207472</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_3">Harris NL, Jaffe ES, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (5): 1361-92, 1994. [<a href="https://pubmed.ncbi.nlm.nih.gov/8068936" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8068936</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_4">Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and Sezary syndrome. Blood 88 (7): 2385-409, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8839829" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8839829</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_5">Agar NS, Wedgeworth E, Crichton S, et al.: Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 (31): 4730-9, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20855822" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20855822</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_6">Talpur R, Singh L, Daulat S, et al.: Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 18 (18): 5051-60, 2012. [<a href="/pmc/articles/PMC3857608/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3857608</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22850569" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22850569</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_7">Kim YH, Liu HL, Mraz-Gernhard S, et al.: Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139 (7): 857-66, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12873880" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12873880</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_8">Alberti-Violetti S, Talpur R, Schlichte M, et al.: Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment. Clin Lymphoma Myeloma Leuk 15 (6): e105-12, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/25817937" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25817937</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_9">Scarisbrick JJ, Prince HM, Vermeer MH, et al.: Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 33 (32): 3766-73, 2015. [<a href="/pmc/articles/PMC4979132/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4979132</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26438120" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26438120</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_10">Kim YH, Jensen RA, Watanabe GL, et al.: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132 (11): 1309-13, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8915308" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8915308</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_11">Vollmer RT: A review of survival in mycosis fungoides. Am J Clin Pathol 141 (5): 706-11, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24713743" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24713743</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_12">Zackheim HS, Amin S, Kashani-Sabet M, et al.: Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 40 (3): 418-25, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10071312" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10071312</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_13">de Coninck EC, Kim YH, Varghese A, et al.: Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 19 (3): 779-84, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11157031" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11157031</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_14">Benton EC, Crichton S, Talpur R, et al.: A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer 49 (13): 2859-68, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/23735705" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23735705</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_15">Huang KP, Weinstock MA, Clarke CA, et al.: Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol 143 (1): 45-50, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17224541" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17224541</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_16">Su C, Nguyen KA, Bai HX, et al.: Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database. J Am Acad Dermatol 77 (3): 497-502.e2, 2017. [<a href="https://pubmed.ncbi.nlm.nih.gov/28645647" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28645647</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_17">Siegel RS, Pandolfino T, Guitart J, et al.: Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 18 (15): 2908-25, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10920140" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10920140</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_18">Lorincz AL: Cutaneous T-cell lymphoma (mycosis fungoides) Lancet 347 (9005): 871-6, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8622396" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8622396</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_19">Quaglino P, Pimpinelli N, Berti E, et al.: Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 118 (23): 5830-9, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22674564" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22674564</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_20">Wernham AG, Shah F, Amel-Kashipaz R, et al.: Stage I mycosis fungoides: frequent association with a favourable prognosis but disease progression and disease-specific mortality may occur. Br J Dermatol 173 (5): 1295-7, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/26053896" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26053896</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_21">Desai M, Liu S, Parker S: Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort. J Am Acad Dermatol 72 (2): 276-85, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/25458019" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25458019</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_22">Olsen EA, Rook AH, Zic J, et al.: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64 (2): 352-404, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21145619" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21145619</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_23">Kubica AW, Davis MD, Weaver AL, et al.: Sézary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol 67 (6): 1189-99, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22640839" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22640839</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_24">Thompson AK, Killian JM, Weaver AL, et al.: Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic. J Am Acad Dermatol 76 (4): 683-688, 2017. [<a href="https://pubmed.ncbi.nlm.nih.gov/28012574" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28012574</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_25">Kim YH, Bishop K, Varghese A, et al.: Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 131 (9): 1003-8, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7661601" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7661601</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_26">Arulogun SO, Prince HM, Ng J, et al.: Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 112 (8): 3082-7, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18647960" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18647960</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_27">Kadin ME, Hughey LC, Wood GS: Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. J Am Acad Dermatol 70 (2): 374-6, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24438952" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24438952</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_28">Benner MF, Jansen PM, Vermeer MH, et al.: Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 119 (7): 1643-9, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22160616" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22160616</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_29">Talpur R, Bassett R, Duvic M: Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 159 (1): 105-12, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18489588" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18489588</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_30">Lebas E, Arrese JE, Nikkels AF: Risk Factors for Skin Infections in Mycosis Fungoides. Dermatology 232 (6): 731-737, 2016. [<a href="https://pubmed.ncbi.nlm.nih.gov/28249285" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28249285</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_1_31">van Santen S, Roach RE, van Doorn R, et al.: Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. JAMA Dermatol 152 (9): 992-1000, 2016. [<a href="https://pubmed.ncbi.nlm.nih.gov/27276223" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27276223</span></a>]</div></li></ol></div></div><div id="CDR0000062881__7"><h2 id="_CDR0000062881__7_">Cellular Classification of Mycosis Fungoides and other Cutaneous T-Cell Lymphomas </h2><p id="CDR0000062881__8">The histological diagnosis of mycosis fungoides and other cutaneous T-cell lymphomas
|
|
is usually difficult to determine in the initial stages of the disease and may require the
|
|
review of multiple biopsies by an experienced pathologist.
|
|
</p><p id="CDR0000062881__9">A definitive diagnosis from a skin biopsy requires the presence of cutaneous T-cell lymphoma cells
|
|
(convoluted lymphocytes), a band-like upper dermal infiltrate, and epidermal
|
|
infiltrations with Pautrier abscesses (collections of neoplastic
|
|
lymphocytes). A definitive diagnosis of Sézary syndrome may be made from a peripheral blood
|
|
evaluation when skin biopsies are consistent with the diagnosis. Supportive evidence for circulating Sézary cells is provided by T-cell receptor gene analysis, identification of the atypical lymphocytes with hyperconvoluted or cerebriform nuclei, and flow cytometry with the characteristic deletion of cell surface markers such as CD7 and CD26. However, none of these is individually pathognomonic for lymphoma.[<a class="bibr" href="#CDR0000062881_rl_7_1" rid="CDR0000062881_rl_7_1">1</a>,<a class="bibr" href="#CDR0000062881_rl_7_2" rid="CDR0000062881_rl_7_2">2</a>]</p><div id="CDR0000062881_rl_7"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062881_rl_7_1">Olsen EA, Rook AH, Zic J, et al.: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64 (2): 352-404, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21145619" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21145619</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_7_2">Fraser-Andrews EA, Russell-Jones R, Woolford AJ, et al.: Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sézary syndrome. Cancer 92 (7): 1745-52, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11745245" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11745245</span></a>]</div></li></ol></div></div><div id="CDR0000062881__10"><h2 id="_CDR0000062881__10_">Stage Information for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas </h2><p id="CDR0000062881__11">The American Joint Committee on Cancer (AJCC) has designated staging by TNM (tumor, node, metastasis) classification to define cutaneous T-cell lymphomas.[<a class="bibr" href="#CDR0000062881_rl_10_1" rid="CDR0000062881_rl_10_1">1</a>] Peripheral blood
|
|
involvement with cutaneous T-cell lymphoma cells is correlated with more
|
|
advanced skin stage, lymph node and visceral involvement, and shortened
|
|
survival. </p><p id="CDR0000062881__214">Cutaneous T-cell lymphomas also have a formal staging system proposed by the International Society for Cutaneous Lymphomas and the European Organisation for Research and Treatment of Cancer.[<a class="bibr" href="#CDR0000062881_rl_10_2" rid="CDR0000062881_rl_10_2">2</a>,<a class="bibr" href="#CDR0000062881_rl_10_3" rid="CDR0000062881_rl_10_3">3</a>]</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCDR0000062881584"><a href="/books/NBK65849/table/CDR0000062881__584/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobCDR0000062881584"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="CDR0000062881__584"><a href="/books/NBK65849/table/CDR0000062881__584/?report=objectonly" target="object" rid-ob="figobCDR0000062881584">Table</a></h4><p class="float-caption no_bottom_margin">Table 1. Histopathological Staging of Lymph Nodes in Cutaneous T-Cell Lymphoma<sup>a</sup>. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCDR0000062881580"><a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobCDR0000062881580"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="CDR0000062881__580"><a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table</a></h4><p class="float-caption no_bottom_margin">Table 2. Definitions of TNM Stages IA and IB<sup>a</sup>. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCDR0000062881581"><a href="/books/NBK65849/table/CDR0000062881__581/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobCDR0000062881581"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="CDR0000062881__581"><a href="/books/NBK65849/table/CDR0000062881__581/?report=objectonly" target="object" rid-ob="figobCDR0000062881581">Table</a></h4><p class="float-caption no_bottom_margin">Table 3. Definitions of TNM Stages IIA and IIB<sup>a</sup>. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCDR0000062881582"><a href="/books/NBK65849/table/CDR0000062881__582/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobCDR0000062881582"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="CDR0000062881__582"><a href="/books/NBK65849/table/CDR0000062881__582/?report=objectonly" target="object" rid-ob="figobCDR0000062881582">Table</a></h4><p class="float-caption no_bottom_margin">Table 4. Definitions of TNM Stages III, IIIA, and IIIB<sup>a</sup>. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCDR0000062881583"><a href="/books/NBK65849/table/CDR0000062881__583/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobCDR0000062881583"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="CDR0000062881__583"><a href="/books/NBK65849/table/CDR0000062881__583/?report=objectonly" target="object" rid-ob="figobCDR0000062881583">Table</a></h4><p class="float-caption no_bottom_margin">Table 5. Definitions of TNM Stages IVA1, IVA2, and IVB<sup>a</sup>. </p></div></div><div id="CDR0000062881_rl_10"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062881_rl_10_1">Primary cutaneous lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 967–72.</div></li><li><div class="bk_ref" id="CDR0000062881_rl_10_2">Olsen E, Vonderheid E, Pimpinelli N, et al.: Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 (6): 1713-22, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17540844" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17540844</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_10_3">Agar NS, Wedgeworth E, Crichton S, et al.: Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 (31): 4730-9, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20855822" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20855822</span></a>]</div></li></ol></div></div><div id="CDR0000062881__50"><h2 id="_CDR0000062881__50_">Treatment Option Overview for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</h2><p id="CDR0000062881__611">Anecdotal responses, some lasting for months, can be seen with aggressive antibiotic treatment of <i>Staphylococcus aureus</i>, with corresponding decreased expression of interleukin-2 receptors, STAT signaling, and T-cell proliferation.[<a class="bibr" href="#CDR0000062881_rl_50_1" rid="CDR0000062881_rl_50_1">1</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]</p><p id="CDR0000062881__132">These types of treatments produce
|
|
remissions, but long-term remissions are uncommon. Therefore, treatment is considered palliative for most patients,
|
|
although major symptomatic improvement is regularly achieved. Survival in excess of 8 years is common for patients with early stages of disease. All patients with cutaneous T-cell lymphomas are
|
|
candidates for clinical trials evaluating new approaches to treatment.
|
|
</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCDR0000062881702"><a href="/books/NBK65849/table/CDR0000062881__702/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobCDR0000062881702"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="CDR0000062881__702"><a href="/books/NBK65849/table/CDR0000062881__702/?report=objectonly" target="object" rid-ob="figobCDR0000062881702">Table</a></h4><p class="float-caption no_bottom_margin">Table 6. Treatment Options for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas. </p></div></div><div id="CDR0000062881_rl_50"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062881_rl_50_1">Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, et al.: Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood 134 (13): 1072-1083, 2019. [<a href="/pmc/articles/PMC6764271/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6764271</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31331920" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31331920</span></a>]</div></li></ol></div></div><div id="CDR0000062881__54"><h2 id="_CDR0000062881__54_">Treatment of Stage I and Stage II Mycosis Fungoides</h2><p id="CDR0000062881__55">Several forms of treatment can produce complete resolution of skin
|
|
lesions in this stage, so the choice of therapy is dependent on local expertise
|
|
and the facilities available. With therapy, the survival of patients with
|
|
stage IA disease can be expected to be the same as for age- and sex-matched
|
|
controls.[<a class="bibr" href="#CDR0000062881_rl_54_1" rid="CDR0000062881_rl_54_1">1</a>-<a class="bibr" href="#CDR0000062881_rl_54_3" rid="CDR0000062881_rl_54_3">3</a>]
|
|
</p><p id="CDR0000062881__347">There is no curative therapy and no clear difference in overall survival (OS) among the treatment options for patients with stage I and stage II mycosis fungoides.</p><p id="CDR0000062881__348">A randomized study of 103 patients compared combined total-skin electron-beam radiation
|
|
(TSEB) plus combination chemotherapy with sequential topical therapies.[<a class="bibr" href="#CDR0000062881_rl_54_4" rid="CDR0000062881_rl_54_4">4</a>] In the latter group, combination
|
|
chemotherapy was reserved for patients with symptomatic extracutaneous disease or disease
|
|
that was refractory to topical therapies. Patients with any disease stage were eligible.
|
|
Although the complete response rate was higher with combined therapy, toxic
|
|
effects were considerably greater, and no difference was seen in disease-free
|
|
survival (DFS) or OS between the two groups.[<a class="bibr" href="#CDR0000062881_rl_54_4" rid="CDR0000062881_rl_54_4">4</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810017/" class="def">Level of evidence A1</a>]
|
|
</p><div id="CDR0000062881__470"><h3>Treatment Options for Stage I and Stage II Mycosis Fungoides </h3><p id="CDR0000062881__471">Treatment options for stages I and II mycosis fungoides include the following:[<a class="bibr" href="#CDR0000062881_rl_54_5" rid="CDR0000062881_rl_54_5">5</a>]
|
|
</p><ol id="CDR0000062881__619"><li class="half_rhythm"><div><a href="#CDR0000062881__620">Photodynamic therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__622">Radiation therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__624">Biological therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__626">Chemotherapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__628">Other drug therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__630">Targeted therapy</a>.</div></li></ol><div id="CDR0000062881__620"><h4>Photodynamic therapy</h4><ol id="CDR0000062881__631"><li class="half_rhythm"><div>Psoralen and ultraviolet A (PUVA) radiation therapy.[<a class="bibr" href="#CDR0000062881_rl_54_6" rid="CDR0000062881_rl_54_6">6</a>-<a class="bibr" href="#CDR0000062881_rl_54_11" rid="CDR0000062881_rl_54_11">11</a>]<ul id="CDR0000062881__632"><li class="half_rhythm"><div>Therapeutic trials with PUVA
|
|
have shown an 80% to 90% complete remission rate in patients, with those in early cutaneous stages
|
|
achieving the best responses. PUVA may be used in conjunction with systemic
|
|
treatment.[<a class="bibr" href="#CDR0000062881_rl_54_10" rid="CDR0000062881_rl_54_10">10</a>] Continued maintenance therapy with PUVA at more
|
|
protracted intervals is generally required to prolong remission duration.[<a class="bibr" href="#CDR0000062881_rl_54_6" rid="CDR0000062881_rl_54_6">6</a>-<a class="bibr" href="#CDR0000062881_rl_54_8" rid="CDR0000062881_rl_54_8">8</a>,<a class="bibr" href="#CDR0000062881_rl_54_10" rid="CDR0000062881_rl_54_10">10</a>]
|
|
PUVA combined with interferon alfa-2a is associated with a high response
|
|
rate.[<a class="bibr" href="#CDR0000062881_rl_54_9" rid="CDR0000062881_rl_54_9">9</a>,<a class="bibr" href="#CDR0000062881_rl_54_10" rid="CDR0000062881_rl_54_10">10</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Narrowband ultraviolet B radiation.[<a class="bibr" href="#CDR0000062881_rl_54_12" rid="CDR0000062881_rl_54_12">12</a>,<a class="bibr" href="#CDR0000062881_rl_54_13" rid="CDR0000062881_rl_54_13">13</a>]<ul id="CDR0000062881__633"><li class="half_rhythm"><div>Single-arm and retrospective comparisons confirm the efficacy of narrowband ultraviolet B with 80% to 90% complete remission rates, especially for patients with early cutaneous stages.[<a class="bibr" href="#CDR0000062881_rl_54_12" rid="CDR0000062881_rl_54_12">12</a>,<a class="bibr" href="#CDR0000062881_rl_54_13" rid="CDR0000062881_rl_54_13">13</a>]</div></li><li class="half_rhythm"><div>A Cochrane systematic review and meta-analysis compared PUVA with narrowband ultraviolet B radiation in 778 patients with early-stage mycosis fungoides (stage IA, IB, and IIA). Significantly higher complete responses were seen in patients treated with PUVA (73.8% vs. 62.2%; hazard ratio, 1.68; 95% confidence interval [CI], 1.02–2.76; <i>P</i> = .04). There were no significant differences in adverse effects.[<a class="bibr" href="#CDR0000062881_rl_54_11" rid="CDR0000062881_rl_54_11">11</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810031/" class="def">Level of evidence B3</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062881__622"><h4>Radiation therapy</h4><ol id="CDR0000062881__634"><li class="half_rhythm"><div>TSEB.[<a class="bibr" href="#CDR0000062881_rl_54_14" rid="CDR0000062881_rl_54_14">14</a>-<a class="bibr" href="#CDR0000062881_rl_54_19" rid="CDR0000062881_rl_54_19">19</a>]<ul id="CDR0000062881__635"><li class="half_rhythm"><div>Electron-beam radiation therapy of
|
|
appropriate energies will penetrate only to the dermis, and thus, the skin alone
|
|
can be treated without systemic effects. This therapy requires a
|
|
radiation therapy facility with physics support and considerable
|
|
technical expertise to deliver precise dosimetry. TSEB can result in short- and long-term cutaneous
|
|
toxic effects and is not widely available. </div></li><li class="half_rhythm"><div>This therapy can provide excellent palliation, with
|
|
complete response rates as high as 80%, and may be combined with systemic treatment. Based on the long-term survival of
|
|
these early-stage patients, electron-beam radiation therapy is sometimes used with
|
|
curative intent.[<a class="bibr" href="#CDR0000062881_rl_54_14" rid="CDR0000062881_rl_54_14">14</a>-<a class="bibr" href="#CDR0000062881_rl_54_18" rid="CDR0000062881_rl_54_18">18</a>] Long-term DFS can be achieved in
|
|
patients with unilesional mycosis fungoides treated with local radiation
|
|
therapy.[<a class="bibr" href="#CDR0000062881_rl_54_19" rid="CDR0000062881_rl_54_19">19</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Local electron-beam radiation or orthovoltage radiation therapy may be
|
|
used to palliate areas of bulky or symptomatic skin disease.[<a class="bibr" href="#CDR0000062881_rl_54_20" rid="CDR0000062881_rl_54_20">20</a>,<a class="bibr" href="#CDR0000062881_rl_54_21" rid="CDR0000062881_rl_54_21">21</a>]</div></li></ol></div><div id="CDR0000062881__624"><h4>Biological therapy</h4><ol id="CDR0000062881__636"><li class="half_rhythm"><div>Interferon alfa
|
|
or interferon gamma alone or in combination with topical therapy.[<a class="bibr" href="#CDR0000062881_rl_54_22" rid="CDR0000062881_rl_54_22">22</a>,<a class="bibr" href="#CDR0000062881_rl_54_23" rid="CDR0000062881_rl_54_23">23</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]<ul id="CDR0000062881__637"><li class="half_rhythm"><div>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the time-to-next-treatment (TTNT) between patients who received interferon alfa and conventional chemotherapy. Interferon alfa provided a longer TTNT of 8.7 months (95% CI, 6.0–18.0) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1) (<i>P</i> < .00001).[<a class="bibr" href="#CDR0000062881_rl_54_23" rid="CDR0000062881_rl_54_23">23</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062881__626"><h4>Chemotherapy</h4><p id="CDR0000062881__705">Chemotherapeutic agents generally demonstrate short durations of response. In a retrospective review of 198 patients with advanced-stage disease, the median TTNT was 4 months.[<a class="bibr" href="#CDR0000062881_rl_54_23" rid="CDR0000062881_rl_54_23">23</a>] However, these comparisons may be confounded by the order in which the agents were introduced.</p><ol id="CDR0000062881__638"><li class="half_rhythm"><div>Topical
|
|
chemotherapy with mechlorethamine.[<a class="bibr" href="#CDR0000062881_rl_54_14" rid="CDR0000062881_rl_54_14">14</a>,<a class="bibr" href="#CDR0000062881_rl_54_24" rid="CDR0000062881_rl_54_24">24</a>,<a class="bibr" href="#CDR0000062881_rl_54_25" rid="CDR0000062881_rl_54_25">25</a>]<ul id="CDR0000062881__639"><li class="half_rhythm"><div>This form of treatment may be
|
|
used palliatively or to supplement therapeutic approaches directed against
|
|
nodal or visceral disease. Topical application of
|
|
mechlorethamine has produced regression of cutaneous lesions, with particular
|
|
efficacy in early stages of disease. The overall complete remission rate is
|
|
related to skin stage; 50% to 80% of TNM classification T1 patients, 25% to 75% of
|
|
T2 patients, as many as 50% of T3
|
|
patients, and 20% to 40% of T4 patients have complete responses. The overall complete remission rate in 243 patients
|
|
was 64% and was related to stage; as many as 35% of stage IV patients had complete
|
|
responses. Treatments are usually continued for 2 to
|
|
3 years. Continuous 5-year DFS may be possible in as many as 33% of T1 patients.[<a class="bibr" href="#CDR0000062881_rl_54_14" rid="CDR0000062881_rl_54_14">14</a>,<a class="bibr" href="#CDR0000062881_rl_54_24" rid="CDR0000062881_rl_54_24">24</a>,<a class="bibr" href="#CDR0000062881_rl_54_25" rid="CDR0000062881_rl_54_25">25</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Oral methotrexate (<a href="https://www.cancer.gov/clinicaltrials/NCT00425555" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCT00425555</a>).[<a class="bibr" href="#CDR0000062881_rl_54_26" rid="CDR0000062881_rl_54_26">26</a>]</div></li><li class="half_rhythm"><div>Pegylated liposomal doxorubicin.[<a class="bibr" href="#CDR0000062881_rl_54_27" rid="CDR0000062881_rl_54_27">27</a>-<a class="bibr" href="#CDR0000062881_rl_54_29" rid="CDR0000062881_rl_54_29">29</a>]</div></li><li class="half_rhythm"><div>Fludarabine, cladribine, and pentostatin are active agents for
|
|
mycosis fungoides.[<a class="bibr" href="#CDR0000062881_rl_54_30" rid="CDR0000062881_rl_54_30">30</a>-<a class="bibr" href="#CDR0000062881_rl_54_33" rid="CDR0000062881_rl_54_33">33</a>]</div></li><li class="half_rhythm"><div>Single-agent chemotherapy or combination systemic chemotherapy (chlorambucil plus prednisone, mechlorethamine,
|
|
cyclophosphamide, methotrexate) is often combined with
|
|
treatment directed at the skin.[<a class="bibr" href="#CDR0000062881_rl_54_4" rid="CDR0000062881_rl_54_4">4</a>,<a class="bibr" href="#CDR0000062881_rl_54_23" rid="CDR0000062881_rl_54_23">23</a>,<a class="bibr" href="#CDR0000062881_rl_54_34" rid="CDR0000062881_rl_54_34">34</a>,<a class="bibr" href="#CDR0000062881_rl_54_35" rid="CDR0000062881_rl_54_35">35</a>]</div></li><li class="half_rhythm"><div>Pralatrexate (folate analogue).[<a class="bibr" href="#CDR0000062881_rl_54_23" rid="CDR0000062881_rl_54_23">23</a>,<a class="bibr" href="#CDR0000062881_rl_54_36" rid="CDR0000062881_rl_54_36">36</a>,<a class="bibr" href="#CDR0000062881_rl_54_37" rid="CDR0000062881_rl_54_37">37</a>]</div></li></ol></div><div id="CDR0000062881__628"><h4>Other drug therapy</h4><ol id="CDR0000062881__643"><li class="half_rhythm"><div>Symptomatic management with topical corticosteroids. Low potency steroids can be used on the face with safety and efficacy.[<a class="bibr" href="#CDR0000062881_rl_54_38" rid="CDR0000062881_rl_54_38">38</a>]</div></li><li class="half_rhythm"><div>Bexarotene, an oral or topical retinoid (<a href="https://www.cancer.gov/clinicaltrials/NCT00255801" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCT00255801</a>).[<a class="bibr" href="#CDR0000062881_rl_54_39" rid="CDR0000062881_rl_54_39">39</a>,<a class="bibr" href="#CDR0000062881_rl_54_40" rid="CDR0000062881_rl_54_40">40</a>]</div></li><li class="half_rhythm"><div>Lenalidomide.[<a class="bibr" href="#CDR0000062881_rl_54_41" rid="CDR0000062881_rl_54_41">41</a>]</div></li><li class="half_rhythm"><div>Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[<a class="bibr" href="#CDR0000062881_rl_54_23" rid="CDR0000062881_rl_54_23">23</a>,<a class="bibr" href="#CDR0000062881_rl_54_42" rid="CDR0000062881_rl_54_42">42</a>-<a class="bibr" href="#CDR0000062881_rl_54_44" rid="CDR0000062881_rl_54_44">44</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]<ul id="CDR0000062881__644"><li class="half_rhythm"><div>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; <i>P</i> = .01).[<a class="bibr" href="#CDR0000062881_rl_54_23" rid="CDR0000062881_rl_54_23">23</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062881__630"><h4>Targeted therapy</h4><ol id="CDR0000062881__645"><li class="half_rhythm"><div>Brentuximab vedotin.[<a class="bibr" href="#CDR0000062881_rl_54_45" rid="CDR0000062881_rl_54_45">45</a>,<a class="bibr" href="#CDR0000062881_rl_54_46" rid="CDR0000062881_rl_54_46">46</a>]<ul id="CDR0000062881__646"><li class="half_rhythm"><div>Two phase II trials of 58 patients with variable CD30 expression showed a 50% to 70% response rate with 50% of patients still in remission after 1 year.[<a class="bibr" href="#CDR0000062881_rl_54_45" rid="CDR0000062881_rl_54_45">45</a>,<a class="bibr" href="#CDR0000062881_rl_54_46" rid="CDR0000062881_rl_54_46">46</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>] </div></li></ul></div></li></ol></div></div><div id="CDR0000062881__TrialSearch_54_sid_5"><h3>Current Clinical Trials</h3><p id="CDR0000062881__TrialSearch_54_22">Use our <a href="https://www.cancer.gov/research/participate/clinical-trials-search/advanced" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/research/participate/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062881_rl_54"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062881_rl_54_1">Kim YH, Jensen RA, Watanabe GL, et al.: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132 (11): 1309-13, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8915308" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8915308</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_2">Zackheim HS, Amin S, Kashani-Sabet M, et al.: Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 40 (3): 418-25, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10071312" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10071312</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_3">Vollmer RT: A review of survival in mycosis fungoides. Am J Clin Pathol 141 (5): 706-11, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24713743" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24713743</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_4">Kaye FJ, Bunn PA, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (26): 1784-90, 1989. [<a href="https://pubmed.ncbi.nlm.nih.gov/2594037" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2594037</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_5">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16574401" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16574401</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_6">Herrmann JJ, Roenigk HH, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33 (2 Pt 1): 234-42, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7622650" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7622650</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_7">Ramsay DL, Lish KM, Yalowitz CB, et al.: Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 128 (7): 931-3, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1626959" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1626959</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_8">Querfeld C, Rosen ST, Kuzel TM, et al.: Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141 (3): 305-11, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/15781671" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15781671</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_9">Kuzel TM, Roenigk HH, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7799028" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7799028</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_10">Olsen EA, Hodak E, Anderson T, et al.: Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol 74 (1): 27-58, 2016. [<a href="https://pubmed.ncbi.nlm.nih.gov/26547257" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26547257</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_11">Phan K, Ramachandran V, Fassihi H, et al.: Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis. JAMA Dermatol 155 (3): 335-341, 2019. [<a href="/pmc/articles/PMC6439931/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6439931</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30698622" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30698622</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_12">Almohideb M, Walsh S, Walsh S, et al.: Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. Clin Lymphoma Myeloma Leuk 17 (9): 604-612, 2017. [<a href="https://pubmed.ncbi.nlm.nih.gov/28711574" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28711574</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_13">Elcin G, Duman N, Karahan S, et al.: Long-term follow-up of early mycosis fungoides patients treated with narrowband ultraviolet B phototherapy. J Dermatolog Treat 25 (3): 268-73, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/23030414" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23030414</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_14">Chinn DM, Chow S, Kim YH, et al.: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 43 (5): 951-8, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10192339" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10192339</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_15">Quirós PA, Jones GW, Kacinski BM, et al.: Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 38 (5): 1027-35, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9276369" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9276369</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_16">Ysebaert L, Truc G, Dalac S, et al.: Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 58 (4): 1128-34, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15001254" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15001254</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_17">Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 85 (9): 1985-95, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10223240" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10223240</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_18">Navi D, Riaz N, Levin YS, et al.: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 147 (5): 561-7, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21576575" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21576575</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_19">Micaily B, Miyamoto C, Kantor G, et al.: Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 42 (2): 361-4, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9788416" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9788416</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_20">Thomas TO, Agrawal P, Guitart J, et al.: Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 (3): 747-53, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22818412" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22818412</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_21">O'Malley JT, de Masson A, Lowry EL, et al.: Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides. Clin Cancer Res 26 (2): 408-418, 2020. [<a href="/pmc/articles/PMC7122012/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7122012</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31636100" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31636100</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_22">Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9 (5): 1089-107, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/8522486" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8522486</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_23">Hughes CF, Khot A, McCormack C, et al.: Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 125 (1): 71-81, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/25336628" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25336628</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_24">Lessin SR, Duvic M, Guitart J, et al.: Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 149 (1): 25-32, 2013. [<a href="/pmc/articles/PMC3662469/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3662469</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23069814" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23069814</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_25">de Quatrebarbes J, Estève E, Bagot M, et al.: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 141 (9): 1117-20, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16172308" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16172308</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_26">Zackheim HS, Kashani-Sabet M, McMillan A: Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 49 (5): 873-8, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/14576667" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14576667</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_27">Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (5): 993-1001, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12942567" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12942567</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_28">Dummer R, Quaglino P, Becker JC, et al.: Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30 (33): 4091-7, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/23045580" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23045580</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_29">Quereux G, Marques S, Nguyen JM, et al.: Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 144 (6): 727-33, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18559761" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18559761</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_30">Saven A, Carrera CJ, Carson DA, et al.: 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80 (3): 587-92, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1353380" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1353380</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_31">Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10 (12): 1907-13, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1453206" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1453206</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_32">Foss FM, Ihde DC, Linnoila IR, et al.: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 12 (10): 2051-9, 1994. [<a href="https://pubmed.ncbi.nlm.nih.gov/7931473" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7931473</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_33">Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 17 (10): 3117-21, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10506607" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10506607</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_34">Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am 9 (5): 1109-16, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/8522487" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8522487</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_35">Zackheim HS, Epstein EH: Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 21 (4 Pt 1): 757-62, 1989. [<a href="https://pubmed.ncbi.nlm.nih.gov/2808792" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2808792</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_36">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22394596" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22394596</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_37">Talpur R, Thompson A, Gangar P, et al.: Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 14 (4): 297-304, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24589156" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24589156</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_38">Duffy R, Jennings T, Kartan S, et al.: Special Considerations in the Treatment of Mycosis Fungoides. Am J Clin Dermatol 20 (4): 571-578, 2019. [<a href="https://pubmed.ncbi.nlm.nih.gov/30993584" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30993584</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_39">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11331325" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11331325</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_40">Heald P, Mehlmauer M, Martin AG, et al.: Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 49 (5): 801-15, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/14576658" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14576658</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_41">Querfeld C, Rosen ST, Guitart J, et al.: Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood 123 (8): 1159-66, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24335103" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24335103</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_42">Duvic M, Dummer R, Becker JC, et al.: Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 49 (2): 386-94, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22981498" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22981498</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_43">Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109-15, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17577020" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17577020</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_44">Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32): 5410-7, 2009. [<a href="/pmc/articles/PMC2773225/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2773225</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19826128" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19826128</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_45">Kim YH, Tavallaee M, Sundram U, et al.: Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol 33 (32): 3750-8, 2015. [<a href="/pmc/articles/PMC5089160/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5089160</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26195720" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26195720</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_54_46">Duvic M, Tetzlaff MT, Gangar P, et al.: Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 33 (32): 3759-65, 2015. [<a href="/pmc/articles/PMC4737859/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4737859</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26261247" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26261247</span></a>]</div></li></ol></div></div><div id="CDR0000062881__73"><h2 id="_CDR0000062881__73_">Treatment of Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome </h2><p id="CDR0000062881__566">
|
|
<b> Mycosis Fungoides </b>
|
|
</p><p id="CDR0000062881__75">There is no curative therapy and no clear difference in overall survival (OS) among the treatment options for patients with stage III and stage IV disease.</p><p id="CDR0000062881__354">The use of single alkylating agents has produced objective responses in 60% of
|
|
patients, with a duration of less than 6 months. One of the alkylating agents
|
|
(e.g., mechlorethamine, cyclophosphamide, or chlorambucil), or the antimetabolite
|
|
methotrexate is the most frequently used. Single agents have not cured any patients, and insufficient data exist to determine whether these
|
|
agents prolong survival. Combination chemotherapy is not definitely superior
|
|
to single agents. Even in patients with stage IV disease, treatments directed at the skin
|
|
may provide significant palliation.
|
|
</p><p id="CDR0000062881__76">A randomized study of 103 patients compared combined total-skin electron-beam radiation
|
|
(TSEB) plus combination chemotherapy with conservation therapy consisting of
|
|
sequential topical therapies.[<a class="bibr" href="#CDR0000062881_rl_73_1" rid="CDR0000062881_rl_73_1">1</a>] In the latter group, combination
|
|
chemotherapy was reserved for patients with symptomatic extracutaneous disease or for disease
|
|
that was refractory to topical therapies. Patients with any disease stage were eligible.
|
|
Although the complete response rate was higher with combined therapy, toxic
|
|
effects were considerably greater, and no difference was seen in disease-free survival
|
|
(DFS) or OS between the two groups.[<a class="bibr" href="#CDR0000062881_rl_73_1" rid="CDR0000062881_rl_73_1">1</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810017/" class="def">Level of evidence A1</a>]
|
|
</p><p id="CDR0000062881__535">
|
|
<b>Sézary Syndrome </b>
|
|
</p><p id="CDR0000062881__552">Sézary syndrome is a rare leukemic variant of cutaneous T-cell lymphoma characterized by erythroderma, circulating Sézary cells with cerebriform nuclei, lymphadenopathy, and pruritus.[<a class="bibr" href="#CDR0000062881_rl_73_2" rid="CDR0000062881_rl_73_2">2</a>] This condition typically progresses rapidly with only short duration of response to most therapies. A retrospective review of 176 patients with Sézary syndrome identified the following poor prognostic factors:[<a class="bibr" href="#CDR0000062881_rl_73_3" rid="CDR0000062881_rl_73_3">3</a>]</p><ul id="CDR0000062881__553"><li class="half_rhythm"><div>High lactate dehydrogenase.</div></li><li class="half_rhythm"><div>Previous diagnosis of mycosis fungoides.</div></li><li class="half_rhythm"><div>Presence of T-cell receptor gene rearrangements in skin, blood, or both.</div></li></ul><p id="CDR0000062881__526">Remissions attained by using extracorporeal photophoresis, interferon alfa, or retinoids may be followed by allogeneic stem cell transplant. In an anecdotal series of 16 patients with Sézary syndrome after allogeneic transplant, 9 were in complete remission after 4 years.[<a class="bibr" href="#CDR0000062881_rl_73_4" rid="CDR0000062881_rl_73_4">4</a>]</p><div id="CDR0000062881__484"><h3>Treatment Options for Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome</h3><p id="CDR0000062881__485">Treatment options for stages III and IV mycosis fungoides and Sézary syndrome include the following (note that in this clinical setting, the skin is
|
|
easily injured; any of the topical therapies must be administered with extreme
|
|
caution):[<a class="bibr" href="#CDR0000062881_rl_73_2" rid="CDR0000062881_rl_73_2">2</a>,<a class="bibr" href="#CDR0000062881_rl_73_5" rid="CDR0000062881_rl_73_5">5</a>]</p><ol id="CDR0000062881__647"><li class="half_rhythm"><div><a href="#CDR0000062881__648">Photodynamic therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__650">Radiation therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__652">Biological therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__654">Chemotherapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__656">Other drug therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__658">Targeted therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__660">Checkpoint inhibitors</a>.</div></li></ol><div id="CDR0000062881__648"><h4>Photodynamic therapy</h4><ol id="CDR0000062881__649"><li class="half_rhythm"><div>Psoralen and ultraviolet A (PUVA) radiation therapy.[<a class="bibr" href="#CDR0000062881_rl_73_6" rid="CDR0000062881_rl_73_6">6</a>-<a class="bibr" href="#CDR0000062881_rl_73_11" rid="CDR0000062881_rl_73_11">11</a>]<ul id="CDR0000062881__662"><li class="half_rhythm"><div>Therapeutic trials with PUVA
|
|
have shown an 80% to 90% complete remission rate in patients, with those in early cutaneous stages
|
|
achieving the best responses. PUVA may be used in conjunction with systemic
|
|
treatment.[<a class="bibr" href="#CDR0000062881_rl_73_10" rid="CDR0000062881_rl_73_10">10</a>] Continued maintenance therapy with PUVA at more
|
|
protracted intervals is generally required to prolong remission duration.[<a class="bibr" href="#CDR0000062881_rl_73_6" rid="CDR0000062881_rl_73_6">6</a>-<a class="bibr" href="#CDR0000062881_rl_73_8" rid="CDR0000062881_rl_73_8">8</a>,<a class="bibr" href="#CDR0000062881_rl_73_10" rid="CDR0000062881_rl_73_10">10</a>]
|
|
PUVA combined with interferon alfa-2a is associated with a high response
|
|
rate.[<a class="bibr" href="#CDR0000062881_rl_73_9" rid="CDR0000062881_rl_73_9">9</a>,<a class="bibr" href="#CDR0000062881_rl_73_10" rid="CDR0000062881_rl_73_10">10</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Narrowband ultraviolet B radiation.[<a class="bibr" href="#CDR0000062881_rl_73_12" rid="CDR0000062881_rl_73_12">12</a>,<a class="bibr" href="#CDR0000062881_rl_73_13" rid="CDR0000062881_rl_73_13">13</a>]<ul id="CDR0000062881__663"><li class="half_rhythm"><div>Single-arm and retrospective comparisons confirm the efficacy of narrowband ultraviolet B with 80% to 90% complete remission rates, especially for patients with early cutaneous stages.[<a class="bibr" href="#CDR0000062881_rl_73_12" rid="CDR0000062881_rl_73_12">12</a>,<a class="bibr" href="#CDR0000062881_rl_73_13" rid="CDR0000062881_rl_73_13">13</a>]</div></li><li class="half_rhythm"><div>A Cochrane systematic review and meta-analysis compared PUVA with narrowband ultraviolet B radiation in 778 patients with early-stage mycosis fungoides (stage IA, IB, and IIA). Significantly higher complete responses were seen in patients treated with PUVA (73.8% vs. 62.2%; hazard ratio, 1.68; 95% confidence interval [CI], 1.02–2.76; <i>P</i> = .04). There were no significant differences in adverse effects.[<a class="bibr" href="#CDR0000062881_rl_73_11" rid="CDR0000062881_rl_73_11">11</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810031/" class="def">Level of evidence B3</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Extracorporeal photophoresis (ECP) alone [<a class="bibr" href="#CDR0000062881_rl_73_14" rid="CDR0000062881_rl_73_14">14</a>-<a class="bibr" href="#CDR0000062881_rl_73_17" rid="CDR0000062881_rl_73_17">17</a>]
|
|
or in combination with
|
|
TSEB.[<a class="bibr" href="#CDR0000062881_rl_73_18" rid="CDR0000062881_rl_73_18">18</a>] ECP is particularly applicable for Sézary syndrome and erythrodermic mycosis fungoides.[<a class="bibr" href="#CDR0000062881_rl_73_17" rid="CDR0000062881_rl_73_17">17</a>]<ul id="CDR0000062881__664"><li class="half_rhythm"><div>In a retrospective analysis of 65 patients, with a median follow-up of 48 months, use of ECP in the first to third line of treatment yielded a longer median time-to-next treatment (TTNT) than other systemic options (<i>P</i> < .03).[<a class="bibr" href="#CDR0000062881_rl_73_17" rid="CDR0000062881_rl_73_17">17</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062881__650"><h4>Radiation therapy</h4><ol id="CDR0000062881__651"><li class="half_rhythm"><div>TSEB.[<a class="bibr" href="#CDR0000062881_rl_73_19" rid="CDR0000062881_rl_73_19">19</a>-<a class="bibr" href="#CDR0000062881_rl_73_24" rid="CDR0000062881_rl_73_24">24</a>]<ul id="CDR0000062881__698"><li class="half_rhythm"><div>Electron-beam radiation therapy of
|
|
appropriate energies will penetrate only to the dermis, and thus, the skin alone
|
|
can be treated without systemic effects. This therapy requires a
|
|
radiation therapy facility with physics support and considerable
|
|
technical expertise to deliver precise dosimetry. TSEB can result in short- and long-term cutaneous
|
|
toxic effects and is not widely available. </div></li><li class="half_rhythm"><div>This therapy can provide excellent palliation, with
|
|
complete response rates as high as 80%, and may be combined with systemic treatment. Based on the long-term survival of
|
|
these early-stage patients, electron-beam radiation therapy is sometimes used with
|
|
curative intent.[<a class="bibr" href="#CDR0000062881_rl_73_19" rid="CDR0000062881_rl_73_19">19</a>-<a class="bibr" href="#CDR0000062881_rl_73_23" rid="CDR0000062881_rl_73_23">23</a>] Long-term DFS can be achieved in
|
|
patients with unilesional mycosis fungoides treated with local radiation
|
|
therapy.[<a class="bibr" href="#CDR0000062881_rl_73_24" rid="CDR0000062881_rl_73_24">24</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Local electron-beam radiation or orthovoltage radiation therapy may
|
|
be used to palliate areas of bulky or symptomatic disease.[<a class="bibr" href="#CDR0000062881_rl_73_25" rid="CDR0000062881_rl_73_25">25</a>,<a class="bibr" href="#CDR0000062881_rl_73_26" rid="CDR0000062881_rl_73_26">26</a>]</div></li></ol></div><div id="CDR0000062881__652"><h4>Biological therapy</h4><ol id="CDR0000062881__653"><li class="half_rhythm"><div>Interferon alfa alone or in combination with other agents, such as topical therapy.[<a class="bibr" href="#CDR0000062881_rl_73_27" rid="CDR0000062881_rl_73_27">27</a>,<a class="bibr" href="#CDR0000062881_rl_73_28" rid="CDR0000062881_rl_73_28">28</a>]<ul id="CDR0000062881__680"><li class="half_rhythm"><div>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the TTNT between patients who received interferon alfa and conventional chemotherapy. Interferon alfa provided a longer TTNT of 8.7 months (95% CI, 6.0–18.0) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1) (<i>P</i> < .00001).[<a class="bibr" href="#CDR0000062881_rl_73_29" rid="CDR0000062881_rl_73_29">29</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062881__654"><h4>Chemotherapy</h4><p id="CDR0000062881__706">Chemotherapeutic agents generally demonstrate short durations of response. In a retrospective review of 198 patients with advanced-stage disease, the median TTNT was 4 months.[<a class="bibr" href="#CDR0000062881_rl_73_29" rid="CDR0000062881_rl_73_29">29</a>] However, these comparisons may be confounded by the order in which the agents were introduced.</p><ol id="CDR0000062881__655"><li class="half_rhythm"><div>Oral methotrexate (<a href="https://www.cancer.gov/clinicaltrials/NCT00425555" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCT00425555</a>).[<a class="bibr" href="#CDR0000062881_rl_73_30" rid="CDR0000062881_rl_73_30">30</a>]</div></li><li class="half_rhythm"><div>Fludarabine, cladribine, and pentostatin are active agents for
|
|
mycosis fungoides and Sézary syndrome.[<a class="bibr" href="#CDR0000062881_rl_73_27" rid="CDR0000062881_rl_73_27">27</a>,<a class="bibr" href="#CDR0000062881_rl_73_29" rid="CDR0000062881_rl_73_29">29</a>,<a class="bibr" href="#CDR0000062881_rl_73_31" rid="CDR0000062881_rl_73_31">31</a>-<a class="bibr" href="#CDR0000062881_rl_73_33" rid="CDR0000062881_rl_73_33">33</a>]</div></li><li class="half_rhythm"><div>Single-agent chemotherapy or combination systemic chemotherapy (chlorambucil plus prednisone, mechlorethamine,
|
|
cyclophosphamide, methotrexate) often combined with
|
|
treatment directed at the skin.[<a class="bibr" href="#CDR0000062881_rl_73_1" rid="CDR0000062881_rl_73_1">1</a>,<a class="bibr" href="#CDR0000062881_rl_73_29" rid="CDR0000062881_rl_73_29">29</a>,<a class="bibr" href="#CDR0000062881_rl_73_34" rid="CDR0000062881_rl_73_34">34</a>,<a class="bibr" href="#CDR0000062881_rl_73_35" rid="CDR0000062881_rl_73_35">35</a>]</div></li><li class="half_rhythm"><div>Topical chemotherapy with mechlorethamine.[<a class="bibr" href="#CDR0000062881_rl_73_36" rid="CDR0000062881_rl_73_36">36</a>,<a class="bibr" href="#CDR0000062881_rl_73_37" rid="CDR0000062881_rl_73_37">37</a>]<ul id="CDR0000062881__683"><li class="half_rhythm"><div>This form of treatment may be
|
|
used palliatively or to supplement therapeutic approaches directed against
|
|
nodal or visceral disease. Topical application of
|
|
mechlorethamine has produced regression of cutaneous lesions, with particular
|
|
efficacy in early stages of disease. The overall complete remission rate is
|
|
related to skin stage; 50% to 80% of TNM classification T1 patients, 25% to 75% of
|
|
T2 patients, as many as 50% of T3
|
|
patients, and 20% to 40% of T4 patients have complete responses. The overall complete remission rate in 243 patients
|
|
was 64% and was related to stage; as many as 35% of stage IV patients had complete
|
|
responses. Treatments are usually continued for 2 to
|
|
3 years. Continuous 5-year DFS may be possible in as many as 33% of T1 patients.[<a class="bibr" href="#CDR0000062881_rl_73_19" rid="CDR0000062881_rl_73_19">19</a>,<a class="bibr" href="#CDR0000062881_rl_73_36" rid="CDR0000062881_rl_73_36">36</a>,<a class="bibr" href="#CDR0000062881_rl_73_37" rid="CDR0000062881_rl_73_37">37</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Pegylated liposomal doxorubicin.[<a class="bibr" href="#CDR0000062881_rl_73_38" rid="CDR0000062881_rl_73_38">38</a>-<a class="bibr" href="#CDR0000062881_rl_73_40" rid="CDR0000062881_rl_73_40">40</a>]</div></li><li class="half_rhythm"><div>Pralatrexate (folate analogue).[<a class="bibr" href="#CDR0000062881_rl_73_29" rid="CDR0000062881_rl_73_29">29</a>,<a class="bibr" href="#CDR0000062881_rl_73_41" rid="CDR0000062881_rl_73_41">41</a>,<a class="bibr" href="#CDR0000062881_rl_73_42" rid="CDR0000062881_rl_73_42">42</a>]</div></li></ol></div><div id="CDR0000062881__656"><h4>Other drug therapy</h4><ol id="CDR0000062881__657"><li class="half_rhythm"><div>Symptomatic management with topical corticosteroids. Low potency steroids can be used on the face with safety and efficacy.[<a class="bibr" href="#CDR0000062881_rl_73_43" rid="CDR0000062881_rl_73_43">43</a>]</div></li><li class="half_rhythm"><div>Lenalidomide.[<a class="bibr" href="#CDR0000062881_rl_73_44" rid="CDR0000062881_rl_73_44">44</a>]</div></li><li class="half_rhythm"><div>Bexarotene, an oral or topical retinoid.[<a class="bibr" href="#CDR0000062881_rl_73_45" rid="CDR0000062881_rl_73_45">45</a>,<a class="bibr" href="#CDR0000062881_rl_73_46" rid="CDR0000062881_rl_73_46">46</a>]</div></li><li class="half_rhythm"><div>Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[<a class="bibr" href="#CDR0000062881_rl_73_2" rid="CDR0000062881_rl_73_2">2</a>,<a class="bibr" href="#CDR0000062881_rl_73_47" rid="CDR0000062881_rl_73_47">47</a>-<a class="bibr" href="#CDR0000062881_rl_73_49" rid="CDR0000062881_rl_73_49">49</a>]<ul id="CDR0000062881__685"><li class="half_rhythm"><div>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; <i>P</i> = .01).[<a class="bibr" href="#CDR0000062881_rl_73_29" rid="CDR0000062881_rl_73_29">29</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062881__658"><h4>Targeted therapy</h4><ol id="CDR0000062881__659"><li class="half_rhythm"><div>Brentuximab vedotin.[<a class="bibr" href="#CDR0000062881_rl_73_50" rid="CDR0000062881_rl_73_50">50</a>,<a class="bibr" href="#CDR0000062881_rl_73_51" rid="CDR0000062881_rl_73_51">51</a>]<ul id="CDR0000062881__686"><li class="half_rhythm"><div>Two phase II trials of 58 patients with variable CD30 expression showed a 50% to 70% response rate with 50% of patients still in remission after 1 year.[<a class="bibr" href="#CDR0000062881_rl_73_50" rid="CDR0000062881_rl_73_50">50</a>,<a class="bibr" href="#CDR0000062881_rl_73_51" rid="CDR0000062881_rl_73_51">51</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>] </div></li></ul></div></li></ol></div><div id="CDR0000062881__660"><h4>Checkpoint inhibitors</h4><ol id="CDR0000062881__661"><li class="half_rhythm"><div>Pembrolizumab.[<a class="bibr" href="#CDR0000062881_rl_73_52" rid="CDR0000062881_rl_73_52">52</a>]<ul id="CDR0000062881__699"><li class="half_rhythm"><div>Anecdotal responses have been seen in patients with advanced relapsed or refractory mycosis fungoides. In a single-arm, multicenter, phase II trial of 24 patients treated with pembrolizumab, the overall response rate was 38%.[<a class="bibr" href="#CDR0000062881_rl_73_52" rid="CDR0000062881_rl_73_52">52</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]</div></li><li class="half_rhythm"><div>There are anecdotal reports of hyperprogression of T-cell malignancies following treatment with immune checkpoint inhibitors.[<a class="bibr" href="#CDR0000062881_rl_73_53" rid="CDR0000062881_rl_73_53">53</a>,<a class="bibr" href="#CDR0000062881_rl_73_54" rid="CDR0000062881_rl_73_54">54</a>]
|
|
</div></li></ul></div></li></ol></div></div><div id="CDR0000062881__TrialSearch_73_sid_6"><h3>Current Clinical Trials</h3><p id="CDR0000062881__TrialSearch_73_22">Use our <a href="https://www.cancer.gov/research/participate/clinical-trials-search/advanced" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/research/participate/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062881_rl_73"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062881_rl_73_1">Kaye FJ, Bunn PA, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (26): 1784-90, 1989. [<a href="https://pubmed.ncbi.nlm.nih.gov/2594037" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2594037</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_2">Olsen EA, Rook AH, Zic J, et al.: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64 (2): 352-404, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21145619" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21145619</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_3">Kubica AW, Davis MD, Weaver AL, et al.: Sézary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol 67 (6): 1189-99, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22640839" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22640839</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_4">Polansky M, Talpur R, Daulat S, et al.: Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. Clin Lymphoma Myeloma Leuk 15 (5): e83-93, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/25458083" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25458083</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_5">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16574401" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16574401</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_6">Herrmann JJ, Roenigk HH, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33 (2 Pt 1): 234-42, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7622650" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7622650</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_7">Ramsay DL, Lish KM, Yalowitz CB, et al.: Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 128 (7): 931-3, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1626959" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1626959</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_8">Querfeld C, Rosen ST, Kuzel TM, et al.: Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141 (3): 305-11, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/15781671" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15781671</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_9">Kuzel TM, Roenigk HH, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7799028" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7799028</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_10">Olsen EA, Hodak E, Anderson T, et al.: Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol 74 (1): 27-58, 2016. [<a href="https://pubmed.ncbi.nlm.nih.gov/26547257" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26547257</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_11">Phan K, Ramachandran V, Fassihi H, et al.: Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis. JAMA Dermatol 155 (3): 335-341, 2019. [<a href="/pmc/articles/PMC6439931/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6439931</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30698622" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30698622</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_12">Almohideb M, Walsh S, Walsh S, et al.: Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. Clin Lymphoma Myeloma Leuk 17 (9): 604-612, 2017. [<a href="https://pubmed.ncbi.nlm.nih.gov/28711574" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28711574</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_13">Elcin G, Duman N, Karahan S, et al.: Long-term follow-up of early mycosis fungoides patients treated with narrowband ultraviolet B phototherapy. J Dermatolog Treat 25 (3): 268-73, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/23030414" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23030414</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_14">Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 316 (6): 297-303, 1987. [<a href="https://pubmed.ncbi.nlm.nih.gov/3543674" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3543674</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_15">Heald PW, Perez MI, McKiernan G, et al.: Extracorporeal photochemotherapy for CTCL. Prog Clin Biol Res 337: 443-7, 1990. [<a href="https://pubmed.ncbi.nlm.nih.gov/2191335" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2191335</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_16">Scarisbrick JJ, Taylor P, Holtick U, et al.: U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 158 (4): 659-78, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18241274" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18241274</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_17">Gao C, McCormack C, van der Weyden C, et al.: Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome. Blood 134 (16): 1346-1350, 2019. [<a href="https://pubmed.ncbi.nlm.nih.gov/31467061" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31467061</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_18">Palareti G, Maccaferri M, Manotti C, et al.: Fibrinogen assays: a collaborative study of six different methods. C.I.S.M.E.L. Comitato Italiano per la Standardizzazione dei Metodi in Ematologia e Laboratorio. Clin Chem 37 (5): 714-9, 1991. [<a href="https://pubmed.ncbi.nlm.nih.gov/2032326" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2032326</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_19">Chinn DM, Chow S, Kim YH, et al.: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 43 (5): 951-8, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10192339" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10192339</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_20">Quirós PA, Jones GW, Kacinski BM, et al.: Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 38 (5): 1027-35, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9276369" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9276369</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_21">Ysebaert L, Truc G, Dalac S, et al.: Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 58 (4): 1128-34, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15001254" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15001254</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_22">Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 85 (9): 1985-95, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10223240" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10223240</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_23">Navi D, Riaz N, Levin YS, et al.: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 147 (5): 561-7, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21576575" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21576575</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_24">Micaily B, Miyamoto C, Kantor G, et al.: Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 42 (2): 361-4, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9788416" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9788416</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_25">Thomas TO, Agrawal P, Guitart J, et al.: Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 (3): 747-53, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22818412" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22818412</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_26">O'Malley JT, de Masson A, Lowry EL, et al.: Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides. Clin Cancer Res 26 (2): 408-418, 2020. [<a href="/pmc/articles/PMC7122012/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7122012</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31636100" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31636100</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_27">Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10 (12): 1907-13, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1453206" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1453206</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_28">Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9 (5): 1089-107, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/8522486" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8522486</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_29">Hughes CF, Khot A, McCormack C, et al.: Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 125 (1): 71-81, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/25336628" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25336628</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_30">Zackheim HS, Kashani-Sabet M, McMillan A: Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 49 (5): 873-8, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/14576667" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14576667</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_31">Saven A, Carrera CJ, Carson DA, et al.: 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80 (3): 587-92, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1353380" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1353380</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_32">Foss FM, Ihde DC, Linnoila IR, et al.: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 12 (10): 2051-9, 1994. [<a href="https://pubmed.ncbi.nlm.nih.gov/7931473" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7931473</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_33">Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 17 (10): 3117-21, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10506607" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10506607</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_34">Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am 9 (5): 1109-16, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/8522487" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8522487</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_35">Zackheim HS, Epstein EH: Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 21 (4 Pt 1): 757-62, 1989. [<a href="https://pubmed.ncbi.nlm.nih.gov/2808792" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2808792</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_36">Lessin SR, Duvic M, Guitart J, et al.: Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 149 (1): 25-32, 2013. [<a href="/pmc/articles/PMC3662469/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3662469</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23069814" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23069814</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_37">de Quatrebarbes J, Estève E, Bagot M, et al.: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 141 (9): 1117-20, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16172308" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16172308</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_38">Dummer R, Quaglino P, Becker JC, et al.: Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30 (33): 4091-7, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/23045580" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23045580</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_39">Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (5): 993-1001, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12942567" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12942567</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_40">Quereux G, Marques S, Nguyen JM, et al.: Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 144 (6): 727-33, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18559761" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18559761</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_41">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22394596" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22394596</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_42">Talpur R, Thompson A, Gangar P, et al.: Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 14 (4): 297-304, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24589156" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24589156</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_43">Duffy R, Jennings T, Kartan S, et al.: Special Considerations in the Treatment of Mycosis Fungoides. Am J Clin Dermatol 20 (4): 571-578, 2019. [<a href="https://pubmed.ncbi.nlm.nih.gov/30993584" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30993584</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_44">Querfeld C, Rosen ST, Guitart J, et al.: Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood 123 (8): 1159-66, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24335103" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24335103</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_45">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11331325" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11331325</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_46">Heald P, Mehlmauer M, Martin AG, et al.: Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 49 (5): 801-15, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/14576658" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14576658</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_47">Duvic M, Dummer R, Becker JC, et al.: Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 49 (2): 386-94, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22981498" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22981498</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_48">Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109-15, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17577020" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17577020</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_49">Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32): 5410-7, 2009. [<a href="/pmc/articles/PMC2773225/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2773225</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19826128" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19826128</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_50">Kim YH, Tavallaee M, Sundram U, et al.: Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol 33 (32): 3750-8, 2015. [<a href="/pmc/articles/PMC5089160/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5089160</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26195720" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26195720</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_51">Duvic M, Tetzlaff MT, Gangar P, et al.: Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 33 (32): 3759-65, 2015. [<a href="/pmc/articles/PMC4737859/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4737859</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26261247" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26261247</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_52">Khodadoust MS, Rook AH, Porcu P, et al.: Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. J Clin Oncol 38 (1): 20-28, 2020. [<a href="/pmc/articles/PMC6943974/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6943974</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31532724" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31532724</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_53">Ratner L, Waldmann TA, Janakiram M, et al.: Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. N Engl J Med 378 (20): 1947-1948, 2018. [<a href="https://pubmed.ncbi.nlm.nih.gov/29768155" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29768155</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_73_54">Bennani NN, Kim HJ, Pederson LD, et al.: Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer 10 (6): , 2022. [<a href="/pmc/articles/PMC9234908/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9234908</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35750419" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35750419</span></a>]</div></li></ol></div></div><div id="CDR0000062881__102"><h2 id="_CDR0000062881__102_">Treatment of Recurrent Mycosis Fungoides and Sézary Syndrome</h2><p id="CDR0000062881__103">The treatment of patients with relapsed mycosis fungoides and Sézary syndrome involves the joint decisions of the dermatologist, medical oncologist, and
|
|
radiation oncologist. It may be possible to re-treat localized areas of
|
|
relapse in the skin with additional electron-beam radiation therapy or to repeat total-skin electron-beam radiation therapy (TSEB).[<a class="bibr" href="#CDR0000062881_rl_102_1" rid="CDR0000062881_rl_102_1">1</a>] Photon radiation to bulky skin or
|
|
nodal masses may prove beneficial. If these options are not possible, then
|
|
continued topical treatment with other modalities such as mechlorethamine or
|
|
psoralen and ultraviolet A radiation (PUVA) may be warranted to relieve
|
|
cutaneous symptoms.
|
|
</p><p id="CDR0000062881__114">Patients should consider clinical trials as a therapeutic
|
|
option.</p><div id="CDR0000062881__498"><h3>Treatment Options for Recurrent Mycosis Fungoides and Sézary Syndrome</h3><p id="CDR0000062881__499">Treatment options under clinical evaluation for recurrent mycosis fungoides and Sézary syndrome include the following:[<a class="bibr" href="#CDR0000062881_rl_102_2" rid="CDR0000062881_rl_102_2">2</a>,<a class="bibr" href="#CDR0000062881_rl_102_3" rid="CDR0000062881_rl_102_3">3</a>]</p><ol id="CDR0000062881__665"><li class="half_rhythm"><div><a href="#CDR0000062881__666">Radiation therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__668">Photodynamic therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__670">Chemotherapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__672">Other drug therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__674">Biological therapy</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__676">Allogeneic stem cell transplant</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062881__678">Targeted therapy</a>.</div></li></ol><div id="CDR0000062881__666"><h4>Radiation therapy</h4><ol id="CDR0000062881__667"><li class="half_rhythm"><div>Additional electron-beam radiation therapy or a repeat of TSEB.<ul id="CDR0000062881__687"><li class="half_rhythm"><div>Electron-beam radiation therapy of
|
|
appropriate energies will penetrate only to the dermis, and thus, the skin alone
|
|
can be treated without systemic effects. This therapy requires a
|
|
radiation therapy facility with physics support and considerable
|
|
technical expertise to deliver precise dosimetry. TSEB can result in short- and long-term cutaneous
|
|
toxic effects and is not widely available. </div></li><li class="half_rhythm"><div>This therapy can provide excellent palliation, with
|
|
complete response rates as high as 80%, and may be combined with systemic treatment. Based on the long-term survival of
|
|
these early-stage patients, electron-beam radiation therapy is sometimes used with
|
|
curative intent.[<a class="bibr" href="#CDR0000062881_rl_102_4" rid="CDR0000062881_rl_102_4">4</a>-<a class="bibr" href="#CDR0000062881_rl_102_8" rid="CDR0000062881_rl_102_8">8</a>] Long-term disease-free survival (DFS) can be achieved in
|
|
patients with unilesional mycosis fungoides treated with local radiation
|
|
therapy.[<a class="bibr" href="#CDR0000062881_rl_102_9" rid="CDR0000062881_rl_102_9">9</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Photon radiation to bulky skin or nodal masses.[<a class="bibr" href="#CDR0000062881_rl_102_10" rid="CDR0000062881_rl_102_10">10</a>]</div></li></ol></div><div id="CDR0000062881__668"><h4>Photodynamic therapy</h4><ol id="CDR0000062881__669"><li class="half_rhythm"><div>PUVA radiation therapy.[<a class="bibr" href="#CDR0000062881_rl_102_11" rid="CDR0000062881_rl_102_11">11</a>-<a class="bibr" href="#CDR0000062881_rl_102_16" rid="CDR0000062881_rl_102_16">16</a>]<ul id="CDR0000062881__688"><li class="half_rhythm"><div>Therapeutic trials with PUVA
|
|
have shown an 80% to 90% complete remission rate in patients, with those in early cutaneous stages
|
|
achieving the best responses. PUVA may be used in conjunction with systemic
|
|
treatment.[<a class="bibr" href="#CDR0000062881_rl_102_15" rid="CDR0000062881_rl_102_15">15</a>] Continued maintenance therapy with PUVA at more
|
|
protracted intervals is generally required to prolong remission duration.[<a class="bibr" href="#CDR0000062881_rl_102_11" rid="CDR0000062881_rl_102_11">11</a>-<a class="bibr" href="#CDR0000062881_rl_102_13" rid="CDR0000062881_rl_102_13">13</a>,<a class="bibr" href="#CDR0000062881_rl_102_15" rid="CDR0000062881_rl_102_15">15</a>]
|
|
PUVA combined with interferon alfa-2a is associated with a high response
|
|
rate.[<a class="bibr" href="#CDR0000062881_rl_102_14" rid="CDR0000062881_rl_102_14">14</a>,<a class="bibr" href="#CDR0000062881_rl_102_15" rid="CDR0000062881_rl_102_15">15</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Narrowband ultraviolet B radiation.[<a class="bibr" href="#CDR0000062881_rl_102_17" rid="CDR0000062881_rl_102_17">17</a>,<a class="bibr" href="#CDR0000062881_rl_102_18" rid="CDR0000062881_rl_102_18">18</a>]<ul id="CDR0000062881__689"><li class="half_rhythm"><div>Single-arm and retrospective comparisons confirm the efficacy of narrowband ultraviolet B with 80% to 90% complete remission rates, especially for patients with early cutaneous stages.[<a class="bibr" href="#CDR0000062881_rl_102_17" rid="CDR0000062881_rl_102_17">17</a>,<a class="bibr" href="#CDR0000062881_rl_102_18" rid="CDR0000062881_rl_102_18">18</a>]</div></li><li class="half_rhythm"><div>A Cochrane systematic review and meta-analysis compared PUVA with narrowband ultraviolet B radiation in 778 patients with early-stage mycosis fungoides (stage IA, IB, and IIA). Significantly higher complete response rates were seen in patients treated with PUVA (73.8% vs. 62.2%; hazard ratio [HR], 1.68; 95% confidence interval [CI], 1.02–2.76; <i>P</i> = .04). There were no significant differences in adverse effects.[<a class="bibr" href="#CDR0000062881_rl_102_16" rid="CDR0000062881_rl_102_16">16</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810031/" class="def">Level of evidence B3</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Extracorporeal photophoresis (ECP) has produced tumor
|
|
regression in patients who are resistant to other therapies.[<a class="bibr" href="#CDR0000062881_rl_102_19" rid="CDR0000062881_rl_102_19">19</a>,<a class="bibr" href="#CDR0000062881_rl_102_20" rid="CDR0000062881_rl_102_20">20</a>]<ul id="CDR0000062881__690"><li class="half_rhythm"><div>In a retrospective analysis of 65 patients, with a median follow-up of 48 months, use of ECP in the first to third line of treatment yielded a longer median time-to-next treatment (TTNT) than other systemic options (<i>P</i> < .03).[<a class="bibr" href="#CDR0000062881_rl_102_21" rid="CDR0000062881_rl_102_21">21</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062881__670"><h4>Chemotherapy</h4><ol id="CDR0000062881__671"><li class="half_rhythm"><div>Topical treatment with mechlorethamine or PUVA.<ul id="CDR0000062881__691"><li class="half_rhythm"><div>This form of treatment may be
|
|
used palliatively or to supplement therapeutic approaches directed against
|
|
nodal or visceral disease. Topical application of
|
|
mechlorethamine has produced regression of cutaneous lesions, with particular
|
|
efficacy in early stages of disease. The overall complete remission rate is
|
|
related to skin stage; 50% to 80% of TNM classification T1 patients, 25% to 75% of
|
|
T2 patients, as many as 50% of T3
|
|
patients, and 20% to 40% of T4 patients have complete responses. The overall complete remission rate in 243 patients
|
|
was 64% and was related to stage; as many as 35% of stage IV patients had complete
|
|
responses. Treatments are usually continued for 2 to
|
|
3 years. Continuous 5-year DFS may be possible in as many as 33% of T1 patients.[<a class="bibr" href="#CDR0000062881_rl_102_4" rid="CDR0000062881_rl_102_4">4</a>,<a class="bibr" href="#CDR0000062881_rl_102_22" rid="CDR0000062881_rl_102_22">22</a>,<a class="bibr" href="#CDR0000062881_rl_102_23" rid="CDR0000062881_rl_102_23">23</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Pralatrexate (folate analogue).[<a class="bibr" href="#CDR0000062881_rl_102_24" rid="CDR0000062881_rl_102_24">24</a>,<a class="bibr" href="#CDR0000062881_rl_102_25" rid="CDR0000062881_rl_102_25">25</a>]<ul id="CDR0000062881__692"><li class="half_rhythm"><div>Chemotherapeutic agents generally yield short durations of response. In a retrospective review of 198 patients with advanced-stage disease, the median TTNT was 4 months.[<a class="bibr" href="#CDR0000062881_rl_102_26" rid="CDR0000062881_rl_102_26">26</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Pegylated liposomal doxorubicin.[<a class="bibr" href="#CDR0000062881_rl_102_27" rid="CDR0000062881_rl_102_27">27</a>-<a class="bibr" href="#CDR0000062881_rl_102_29" rid="CDR0000062881_rl_102_29">29</a>]</div></li><li class="half_rhythm"><div>Systemic chemotherapy: chlorambucil plus prednisone, mechlorethamine,
|
|
cyclophosphamide, methotrexate, and combination chemotherapy.[<a class="bibr" href="#CDR0000062881_rl_102_26" rid="CDR0000062881_rl_102_26">26</a>,<a class="bibr" href="#CDR0000062881_rl_102_30" rid="CDR0000062881_rl_102_30">30</a>-<a class="bibr" href="#CDR0000062881_rl_102_32" rid="CDR0000062881_rl_102_32">32</a>]</div></li></ol></div><div id="CDR0000062881__672"><h4>Other drug therapy</h4><ol id="CDR0000062881__673"><li class="half_rhythm"><div>Symptomatic management with topical corticosteroids.</div></li><li class="half_rhythm"><div>Bexarotene, an oral or topical retinoid.[<a class="bibr" href="#CDR0000062881_rl_102_33" rid="CDR0000062881_rl_102_33">33</a>,<a class="bibr" href="#CDR0000062881_rl_102_34" rid="CDR0000062881_rl_102_34">34</a>]</div></li><li class="half_rhythm"><div>Lenalidomide.[<a class="bibr" href="#CDR0000062881_rl_102_35" rid="CDR0000062881_rl_102_35">35</a>]</div></li><li class="half_rhythm"><div>Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[<a class="bibr" href="#CDR0000062881_rl_102_36" rid="CDR0000062881_rl_102_36">36</a>-<a class="bibr" href="#CDR0000062881_rl_102_38" rid="CDR0000062881_rl_102_38">38</a>]<ul id="CDR0000062881__700"><li class="half_rhythm"><div>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; <i>P</i> = .01).[<a class="bibr" href="#CDR0000062881_rl_102_26" rid="CDR0000062881_rl_102_26">26</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062881__674"><h4>Biological therapy</h4><ol id="CDR0000062881__675"><li class="half_rhythm"><div>Interferon alfa alone or in combination with other agents, such as topical therapy.[<a class="bibr" href="#CDR0000062881_rl_102_39" rid="CDR0000062881_rl_102_39">39</a>,<a class="bibr" href="#CDR0000062881_rl_102_40" rid="CDR0000062881_rl_102_40">40</a>]<ul id="CDR0000062881__693"><li class="half_rhythm"><div>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the TTNT between patients who received interferon alfa and conventional chemotherapy. Interferon alfa provided a longer TTNT of 8.7 months (95% CI, 6.0–18.0) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1) (<i>P</i> < .00001).[<a class="bibr" href="#CDR0000062881_rl_102_26" rid="CDR0000062881_rl_102_26">26</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062881__676"><h4>Allogeneic stem cell transplant</h4><ol id="CDR0000062881__677"><li class="half_rhythm"><div>Allogeneic stem cell transplant (SCT).[<a class="bibr" href="#CDR0000062881_rl_102_41" rid="CDR0000062881_rl_102_41">41</a>-<a class="bibr" href="#CDR0000062881_rl_102_43" rid="CDR0000062881_rl_102_43">43</a>,<a class="bibr" href="#CDR0000062881_rl_102_43" rid="CDR0000062881_rl_102_43">43</a>-<a class="bibr" href="#CDR0000062881_rl_102_45" rid="CDR0000062881_rl_102_45">45</a>]<ul id="CDR0000062881__694"><li class="half_rhythm"><div>Among highly selected patients, the 5-year overall survival (OS) rate ranges from 30% to 50%, with a relapse-free survival rate of 15% to 25%.[<a class="bibr" href="#CDR0000062881_rl_102_41" rid="CDR0000062881_rl_102_41">41</a>-<a class="bibr" href="#CDR0000062881_rl_102_45" rid="CDR0000062881_rl_102_45">45</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062881__678"><h4>Targeted therapy</h4><ol id="CDR0000062881__679"><li class="half_rhythm"><div class="half_rhythm">Brentuximab vedotin.[<a class="bibr" href="#CDR0000062881_rl_102_46" rid="CDR0000062881_rl_102_46">46</a>,<a class="bibr" href="#CDR0000062881_rl_102_47" rid="CDR0000062881_rl_102_47">47</a>]<ul id="CDR0000062881__695"><li class="half_rhythm"><div>Two phase II trials of 58 patients with variable CD30 expression showed a 50% to 70% response rate with 50% of patients still in remission after 1 year.[<a class="bibr" href="#CDR0000062881_rl_102_46" rid="CDR0000062881_rl_102_46">46</a>,<a class="bibr" href="#CDR0000062881_rl_102_47" rid="CDR0000062881_rl_102_47">47</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>] </div></li></ul></div></li><li class="half_rhythm"><div class="half_rhythm">Mogamulizumab.[<a class="bibr" href="#CDR0000062881_rl_102_48" rid="CDR0000062881_rl_102_48">48</a>]<ol id="CDR0000062881__696" class="lower-alpha"><li class="half_rhythm"><div>In a prospective randomized trial, 372 previously treated patients received either mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, or the HDACi vorinostat. <ul id="CDR0000062881__697"><li class="half_rhythm"><div>With a median follow-up of 17 months, the median progression-free survival was 7.7 months for patients who received mogamulizumab and 3.1 months for patients who received vorinostat (HR, 0.53; 95% CI, 0.41−0.69; <i>P</i> < .0001).[<a class="bibr" href="#CDR0000062881_rl_102_48" rid="CDR0000062881_rl_102_48">48</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810025/" class="def">Level of evidence B1</a>]</div></li><li class="half_rhythm"><div> Mogamulizumab appeared to be especially effective in patients with blood involvement, such as those with Sézary syndrome.</div></li><li class="half_rhythm"><div>This preliminary study was not designed to detect differences in OS.</div></li></ul></div></li></ol></div><div class="half_rhythm">Mogamulizumab is often avoided in patients scheduled to undergo allogeneic SCT, based on data from a Japanese study that showed an increased risk of severe graft-versus-host disease (GVHD) in patients treated with mogamulizumab beforehand.[<a class="bibr" href="#CDR0000062881_rl_102_49" rid="CDR0000062881_rl_102_49">49</a>] The relevance of these findings in other countries and the impact of different GVHD prophylaxis regimens in these patients remains to be determined.</div></li></ol></div></div><div id="CDR0000062881__TrialSearch_102_sid_7"><h3>Current Clinical Trials</h3><p id="CDR0000062881__TrialSearch_102_22">Use our <a href="https://www.cancer.gov/research/participate/clinical-trials-search/advanced" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/research/participate/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062881_rl_102"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062881_rl_102_1">Becker M, Hoppe RT, Knox SJ: Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys 32 (5): 1445-9, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7635786" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7635786</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_2">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16574401" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16574401</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_3">Prince HM, Duvic M, Martin A, et al.: Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28 (11): 1870-7, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20212249" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20212249</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_4">Chinn DM, Chow S, Kim YH, et al.: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 43 (5): 951-8, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10192339" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10192339</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_5">Quirós PA, Jones GW, Kacinski BM, et al.: Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 38 (5): 1027-35, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9276369" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9276369</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_6">Ysebaert L, Truc G, Dalac S, et al.: Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 58 (4): 1128-34, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15001254" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15001254</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_7">Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 85 (9): 1985-95, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10223240" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10223240</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_8">Navi D, Riaz N, Levin YS, et al.: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 147 (5): 561-7, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21576575" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21576575</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_9">Micaily B, Miyamoto C, Kantor G, et al.: Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 42 (2): 361-4, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9788416" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9788416</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_10">Thomas TO, Agrawal P, Guitart J, et al.: Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 (3): 747-53, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22818412" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22818412</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_11">Herrmann JJ, Roenigk HH, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33 (2 Pt 1): 234-42, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7622650" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7622650</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_12">Ramsay DL, Lish KM, Yalowitz CB, et al.: Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 128 (7): 931-3, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1626959" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1626959</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_13">Querfeld C, Rosen ST, Kuzel TM, et al.: Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141 (3): 305-11, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/15781671" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15781671</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_14">Kuzel TM, Roenigk HH, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7799028" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7799028</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_15">Olsen EA, Hodak E, Anderson T, et al.: Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol 74 (1): 27-58, 2016. [<a href="https://pubmed.ncbi.nlm.nih.gov/26547257" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26547257</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_16">Phan K, Ramachandran V, Fassihi H, et al.: Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis. JAMA Dermatol 155 (3): 335-341, 2019. [<a href="/pmc/articles/PMC6439931/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6439931</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30698622" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30698622</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_17">Almohideb M, Walsh S, Walsh S, et al.: Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. Clin Lymphoma Myeloma Leuk 17 (9): 604-612, 2017. [<a href="https://pubmed.ncbi.nlm.nih.gov/28711574" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28711574</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_18">Elcin G, Duman N, Karahan S, et al.: Long-term follow-up of early mycosis fungoides patients treated with narrowband ultraviolet B phototherapy. J Dermatolog Treat 25 (3): 268-73, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/23030414" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23030414</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_19">Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 316 (6): 297-303, 1987. [<a href="https://pubmed.ncbi.nlm.nih.gov/3543674" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3543674</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_20">Heald PW, Perez MI, McKiernan G, et al.: Extracorporeal photochemotherapy for CTCL. Prog Clin Biol Res 337: 443-7, 1990. [<a href="https://pubmed.ncbi.nlm.nih.gov/2191335" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2191335</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_21">Gao C, McCormack C, van der Weyden C, et al.: Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome. Blood 134 (16): 1346-1350, 2019. [<a href="https://pubmed.ncbi.nlm.nih.gov/31467061" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31467061</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_22">Lessin SR, Duvic M, Guitart J, et al.: Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 149 (1): 25-32, 2013. [<a href="/pmc/articles/PMC3662469/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3662469</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23069814" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23069814</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_23">de Quatrebarbes J, Estève E, Bagot M, et al.: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 141 (9): 1117-20, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16172308" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16172308</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_24">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22394596" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22394596</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_25">Talpur R, Thompson A, Gangar P, et al.: Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 14 (4): 297-304, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24589156" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24589156</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_26">Hughes CF, Khot A, McCormack C, et al.: Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 125 (1): 71-81, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/25336628" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25336628</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_27">Dummer R, Quaglino P, Becker JC, et al.: Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30 (33): 4091-7, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/23045580" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23045580</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_28">Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (5): 993-1001, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12942567" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12942567</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_29">Quereux G, Marques S, Nguyen JM, et al.: Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 144 (6): 727-33, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18559761" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18559761</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_30">Kaye FJ, Bunn PA, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (26): 1784-90, 1989. [<a href="https://pubmed.ncbi.nlm.nih.gov/2594037" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2594037</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_31">Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am 9 (5): 1109-16, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/8522487" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8522487</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_32">Zackheim HS, Epstein EH: Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 21 (4 Pt 1): 757-62, 1989. [<a href="https://pubmed.ncbi.nlm.nih.gov/2808792" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2808792</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_33">Miller VA, Benedetti FM, Rigas JR, et al.: Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15 (2): 790-5, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9053506" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9053506</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_34">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11331325" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11331325</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_35">Querfeld C, Rosen ST, Guitart J, et al.: Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood 123 (8): 1159-66, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24335103" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24335103</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_36">Duvic M, Dummer R, Becker JC, et al.: Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 49 (2): 386-94, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22981498" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22981498</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_37">Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109-15, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17577020" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17577020</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_38">Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32): 5410-7, 2009. [<a href="/pmc/articles/PMC2773225/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2773225</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19826128" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19826128</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_39">Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10 (12): 1907-13, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1453206" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1453206</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_40">Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9 (5): 1089-107, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/8522486" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8522486</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_41">Molina A, Zain J, Arber DA, et al.: Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 23 (25): 6163-71, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16135483" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16135483</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_42">Duvic M, Donato M, Dabaja B, et al.: Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 28 (14): 2365-72, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20351328" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20351328</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_43">Duarte RF, Boumendil A, Onida F, et al.: Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol 32 (29): 3347-8, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/25154828" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25154828</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_44">Schlaak M, Pickenhain J, Theurich S, et al.: Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 1: CD008908, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22258991" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22258991</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_45">Lechowicz MJ, Lazarus HM, Carreras J, et al.: Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant 49 (11): 1360-5, 2014. [<a href="/pmc/articles/PMC4221526/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4221526</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25068422" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25068422</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_46">Kim YH, Tavallaee M, Sundram U, et al.: Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol 33 (32): 3750-8, 2015. [<a href="/pmc/articles/PMC5089160/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5089160</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26195720" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26195720</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_47">Duvic M, Tetzlaff MT, Gangar P, et al.: Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 33 (32): 3759-65, 2015. [<a href="/pmc/articles/PMC4737859/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4737859</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26261247" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26261247</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_48">Kim YH, Bagot M, Pinter-Brown L, et al.: Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19 (9): 1192-1204, 2018. [<a href="https://pubmed.ncbi.nlm.nih.gov/30100375" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30100375</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_102_49">Sugio T, Kato K, Aoki T, et al.: Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 22 (9): 1608-1614, 2016. [<a href="https://pubmed.ncbi.nlm.nih.gov/27220263" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27220263</span></a>]</div></li></ol></div></div><div id="CDR0000062881__613"><h2 id="_CDR0000062881__613_">Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma</h2><p id="CDR0000062881__614">Primary cutaneous anaplastic large cell lymphoma presents in the skin only with no preexisting lymphoproliferative disease and no extracutaneous sites of involvement.[<a class="bibr" href="#CDR0000062881_rl_613_1" rid="CDR0000062881_rl_613_1">1</a>-<a class="bibr" href="#CDR0000062881_rl_613_3" rid="CDR0000062881_rl_613_3">3</a>] Patients with this type of lymphoma have disease ranging from clinically benign lymphomatoid papulosis, marked by localized nodules that may regress spontaneously, to progressive and systemic illness requiring aggressive doxorubicin-based combination chemotherapy. This spectrum has been called the primary cutaneous CD30-positive T-cell lymphoproliferative disorder.</p><p id="CDR0000062881__615">Patients with localized disease usually undergo radiation therapy. With more disseminated involvement, watchful waiting or doxorubicin-based combination chemotherapy is used.[<a class="bibr" href="#CDR0000062881_rl_613_1" rid="CDR0000062881_rl_613_1">1</a>-<a class="bibr" href="#CDR0000062881_rl_613_3" rid="CDR0000062881_rl_613_3">3</a>]</p><div id="CDR0000062881__TrialSearch_613_sid_8"><h3>Current Clinical Trials</h3><p id="CDR0000062881__TrialSearch_613_22">Use our <a href="https://www.cancer.gov/research/participate/clinical-trials-search/advanced" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/research/participate/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062881_rl_613"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062881_rl_613_1">de Bruin PC, Beljaards RC, van Heerde P, et al.: Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology 23 (2): 127-35, 1993. [<a href="https://pubmed.ncbi.nlm.nih.gov/8406384" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8406384</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_613_2">Willemze R, Beljaards RC: Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 28 (6): 973-80, 1993. [<a href="https://pubmed.ncbi.nlm.nih.gov/8388410" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8388410</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_613_3">Kempf W, Pfaltz K, Vermeer MH, et al.: EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118 (15): 4024-35, 2011. [<a href="/pmc/articles/PMC3204726/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3204726</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21841159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21841159</span></a>]</div></li></ol></div></div><div id="CDR0000062881__617"><h2 id="_CDR0000062881__617_">Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma</h2><p id="CDR0000062881__618">Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is localized to subcutaneous tissue and can be associated with hemophagocytic lymphohistiocytosis (HLH).[<a class="bibr" href="#CDR0000062881_rl_617_1" rid="CDR0000062881_rl_617_1">1</a>-<a class="bibr" href="#CDR0000062881_rl_617_4" rid="CDR0000062881_rl_617_4">4</a>] Anecdotal reports suggest that the presence or absence of HLH is an important prognostic indicator.[<a class="bibr" href="#CDR0000062881_rl_617_5" rid="CDR0000062881_rl_617_5">5</a>] Patients with SPTCL have cells that express alpha-beta phenotype. </p><p id="CDR0000062881__701">Patients with gamma-delta phenotype have a more aggressive clinical course that is instead classified as primary cutaneous gamma-delta T-cell lymphoma.[<a class="bibr" href="#CDR0000062881_rl_617_6" rid="CDR0000062881_rl_617_6">6</a>-<a class="bibr" href="#CDR0000062881_rl_617_8" rid="CDR0000062881_rl_617_8">8</a>] For more information, see <a href="/books/n/pdqcis/CDR0000811763/?report=reader">Peripheral T-Cell Non-Hodgkin Lymphoma Treatment</a>.</p><p id="CDR0000062881__716">The management of SPTCL depends on the clinical presentation—including the severity of symptoms, cytopenias, and the presence or absence of HLH—and the apparent disease trajectory and aggressiveness. Indolent or smoldering forms of SPTCL are often treated with immunosuppression, including oral methotrexate [<a class="bibr" href="#CDR0000062881_rl_617_9" rid="CDR0000062881_rl_617_9">9</a>] or cyclosporine.[<a class="bibr" href="#CDR0000062881_rl_617_10" rid="CDR0000062881_rl_617_10">10</a>] In contrast, aggressive forms are frequently treated with combination chemotherapy such as CHO(E)P (cyclophosphamide, doxorubicin, vincristine, and prednisone with or without etoposide) with variable responses per anecdotal reports.[<a class="bibr" href="#CDR0000062881_rl_617_11" rid="CDR0000062881_rl_617_11">11</a>] The JAK2 inhibitor ruxolitinib has also been used in SPTCL with associated HLH, including anecdotal reports of responses in patients with disease that did not respond to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy.[<a class="bibr" href="#CDR0000062881_rl_617_12" rid="CDR0000062881_rl_617_12">12</a>] In cases of particularly aggressive or relapsed disease, consolidation with allogeneic stem cell transplant has also been used.[<a class="bibr" href="#CDR0000062881_rl_617_13" rid="CDR0000062881_rl_617_13">13</a>,<a class="bibr" href="#CDR0000062881_rl_617_14" rid="CDR0000062881_rl_617_14">14</a>]</p><div id="CDR0000062881__TrialSearch_617_sid_9"><h3>Current Clinical Trials</h3><p id="CDR0000062881__TrialSearch_617_22">Use our <a href="https://www.cancer.gov/research/participate/clinical-trials-search/advanced" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/research/participate/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062881_rl_617"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062881_rl_617_1">Go RS, Wester SM: Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer 101 (6): 1404-13, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15368328" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15368328</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_2">Marzano AV, Berti E, Paulli M, et al.: Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol 136 (7): 889-96, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10890991" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10890991</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_3">Hoque SR, Child FJ, Whittaker SJ, et al.: Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol 148 (3): 516-25, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12653744" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12653744</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_4">Salhany KE, Macon WR, Choi JK, et al.: Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 22 (7): 881-93, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9669350" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9669350</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_5">Willemze R: Cutaneous lymphomas with a panniculitic presentation. Semin Diagn Pathol 34 (1): 36-43, 2017. [<a href="https://pubmed.ncbi.nlm.nih.gov/27986433" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27986433</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_6">Massone C, Chott A, Metze D, et al.: Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol 28 (6): 719-35, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15166664" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15166664</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_7">Arnulf B, Copie-Bergman C, Delfau-Larue MH, et al.: Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 91 (5): 1723-31, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9473239" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9473239</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_8">Toro JR, Liewehr DJ, Pabby N, et al.: Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 101 (9): 3407-12, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12522013" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12522013</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_9">Grinich E, Koon SM, Cascio MJ, et al.: Subcutaneous panniculitis-like T-cell lymphoma responsive to combination therapy with methotrexate and corticosteroids. Dermatol Online J 24 (9): , 2018. [<a href="https://pubmed.ncbi.nlm.nih.gov/30677832" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30677832</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_10">Rojnuckarin P, Nakorn TN, Assanasen T, et al.: Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma 48 (3): 560-3, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17454599" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17454599</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_11">Willemze R, Jansen PM, Cerroni L, et al.: Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 111 (2): 838-45, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/17934071" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17934071</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_12">Lévy R, Fusaro M, Guerin F, et al.: Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis. Blood Adv 4 (7): 1383-1387, 2020. [<a href="/pmc/articles/PMC7160282/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7160282</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32271897" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32271897</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_13">Weng W, Iragavarapu C, Weng GM, et al.: Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma. Blood Neoplasia 1 (2): 2024.</div></li><li><div class="bk_ref" id="CDR0000062881_rl_617_14">Ichii M, Hatanaka K, Imakita M, et al.: Successful treatment of refractory subcutaneous panniculitis-like T-cell lymphoma with allogeneic peripheral blood stem cell transplantation from HLA-mismatched sibling donor. Leuk Lymphoma 47 (10): 2250-2, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/17071503" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17071503</span></a>]</div></li></ol></div></div><div id="CDR0000062881__717"><h2 id="_CDR0000062881__717_">Treatment of Primary Cutaneous Gamma-Delta T-Cell Lymphoma</h2><p id="CDR0000062881__718">Primary cutaneous gamma-delta T-cell lymphoma (PCGDTCL) is a rare and extremely aggressive form of cutaneous T-cell lymphoma associated with a poor prognosis. These patients may manifest involvement of the epidermis, dermis, subcutaneous region, or mucosa with or without ulceration. PCGDTCL is treated similarly to the most aggressive peripheral T-cell lymphomas, with CHO(E)P (cyclophosphamide doxorubicin, vincristine, and prednisone with or without etoposide).[<a class="bibr" href="#CDR0000062881_rl_717_1" rid="CDR0000062881_rl_717_1">1</a>-<a class="bibr" href="#CDR0000062881_rl_717_5" rid="CDR0000062881_rl_717_5">5</a>] For patients achieving remission, there are reports of prolonged survival following consolidation with allogeneic stem cell transplant.[<a class="bibr" href="#CDR0000062881_rl_717_6" rid="CDR0000062881_rl_717_6">6</a>] </p><div id="CDR0000062881__TrialSearch_717_sid_10"><h3>Current Clinical Trials</h3><p id="CDR0000062881__TrialSearch_717_22">Use our <a href="https://www.cancer.gov/research/participate/clinical-trials-search/advanced" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/research/participate/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062881_rl_717"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062881_rl_717_1">Arnulf B, Copie-Bergman C, Delfau-Larue MH, et al.: Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 91 (5): 1723-31, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9473239" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9473239</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_717_2">Toro JR, Liewehr DJ, Pabby N, et al.: Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 101 (9): 3407-12, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12522013" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12522013</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_717_3">Le Gouill S, Milpied N, Buzyn A, et al.: Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 26 (14): 2264-71, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18390969" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18390969</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_717_4">Pro B, Allen P, Behdad A: Hepatosplenic T-cell lymphoma: a rare but challenging entity. Blood 136 (18): 2018-2026, 2020. [<a href="/pmc/articles/PMC7596851/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7596851</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32756940" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32756940</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_717_5">Alberti-Violetti S, Maronese CA, Venegoni L, et al.: Primary Cutaneous Gamma-Delta T Cell Lymphomas: A Case Series and Overview of the Literature. Dermatopathology (Basel) 8 (4): 515-524, 2021. [<a href="/pmc/articles/PMC8628721/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8628721</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34842638" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34842638</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062881_rl_717_6">Isufi I, Seropian S, Gowda L, et al.: Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leuk Lymphoma 61 (12): 2955-2961, 2020. [<a href="https://pubmed.ncbi.nlm.nih.gov/32643494" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32643494</span></a>]</div></li></ol></div></div><div id="CDR0000062881__719"><h2 id="_CDR0000062881__719_">Treatment of Primary Cutaneous Aggressive Epidermotropic CD8-Positive T-Cell Lymphoma</h2><p id="CDR0000062881__720">Primary cutaneous aggressive epidermotropic CD8-positive T-cell lymphoma is another rare and especially aggressive form of cutaneous T-cell lymphoma. Patients typically present with ulcerative plaques or tumors, and mucosal involvement is common. Neoplastic cells are characterized by expression of CD8 and a cytotoxic phenotype.Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation. Multimodal chemotherapy, such as CHO(E)P (cyclophosphamide, doxorubicin, vincristine, and prednisone with or without etoposide), is often used. Outcomes are generally poor, and prolonged remissions are extremely uncommon in the absence of allogeneic stem cell transplant.[<a class="bibr" href="#CDR0000062881_rl_719_1" rid="CDR0000062881_rl_719_1">1</a>] </p><div id="CDR0000062881__TrialSearch_719_sid_11"><h3>Current Clinical Trials</h3><p id="CDR0000062881__TrialSearch_719_22">Use our <a href="https://www.cancer.gov/research/participate/clinical-trials-search/advanced" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/research/participate/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062881_rl_719"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062881_rl_719_1">Guitart J, Martinez-Escala ME, Subtil A, et al.: Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. Mod Pathol 30 (5): 761-772, 2017. [<a href="/pmc/articles/PMC5413429/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5413429</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28128277" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28128277</span></a>]</div></li></ol></div></div><div id="CDR0000062881__329"><h2 id="_CDR0000062881__329_">Key References for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</h2><p id="CDR0000062881__333">These references have been identified by members of the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Adult Treatment Editorial Board</a> as significant in the field of mycosis fungoides and other cutaneous T-cell lymphoma treatment. This list is provided to inform users of important studies that have helped shape the current understanding of and treatment options for MF/SS. Listed after each reference are the sections within this summary where the reference is cited.</p><ul id="CDR0000062881__330"><li class="half_rhythm"><div>Agar NS, Wedgeworth E, Crichton S, et al.: Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 (31): 4730-9, 2010. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20855822" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PUBMED Abstract</a>]</div><div>Cited in:<ul id="CDR0000062881__339"><li class="half_rhythm"><div><a href="#CDR0000062881__1">General Information About Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</a></div></li><li class="half_rhythm"><div><a href="#CDR0000062881__10">Stage Information for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</a></div></li></ul></div></li><li class="half_rhythm"><div>Hughes CF, Khot A, McCormack C, et al.: Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 125 (1): 71-81, 2015. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/25336628" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PUBMED Abstract</a>]</div><div>Cited in:<ul id="CDR0000062881__337"><li class="half_rhythm"><div><a href="#CDR0000062881__54">Treatment of Stage I and Stage II Mycosis Fungoides</a></div></li><li class="half_rhythm"><div><a href="#CDR0000062881__73">Treatment of Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome</a></div></li><li class="half_rhythm"><div><a href="#CDR0000062881__102">Treatment of Recurrent Mycosis Fungoides and Sézary Syndrome</a></div></li></ul></div></li><li class="half_rhythm"><div>Kadin ME, Hughey LC, Wood GS: Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. J Am Acad Dermatol 70 (2): 374-6, 2014. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/24438952" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PUBMED Abstract</a>]</div><div>Cited in:<ul id="CDR0000062881__335"><li class="half_rhythm"><div><a href="#CDR0000062881__1">General Information About Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</a></div></li></ul></div></li><li class="half_rhythm"><div> Quaglino P, Pimpinelli N, Berti E, et al.: Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 118 (23): 5830-9, 2012. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22674564" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PUBMED Abstract</a>]</div><div>Cited in:<ul id="CDR0000062881__332"><li class="half_rhythm"><div><a href="#CDR0000062881__1">General Information About Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</a></div></li></ul></div></li><li class="half_rhythm"><div>Talpur R, Singh L, Daulat S, et al.: Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 18 (18): 5051-60, 2012. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22850569" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PUBMED Abstract</a>]</div><div>Cited in:<ul id="CDR0000062881__341"><li class="half_rhythm"><div><a href="#CDR0000062881__1">General Information About Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</a></div></li></ul></div></li></ul></div><div id="CDR0000062881__212"><h2 id="_CDR0000062881__212_">Latest Updates to This Summary (08/16/2024)</h2><p id="CDR0000062881__213">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</p><p id="CDR0000062881__721">
|
|
<b>
|
|
<a href="#CDR0000062881__10">Stage Information for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</a>
|
|
</b>
|
|
</p><p id="CDR0000062881__722">Revised <a href="/books/NBK65849/table/CDR0000062881__583/?report=objectonly" target="object" rid-ob="figobCDR0000062881583">Table 5</a>, Definitions of TNM Stages IVA1, IVA2, and IVB to include peripheral blood involvement criteria for B2.</p><p id="CDR0000062881__734">
|
|
<b>
|
|
<a href="#CDR0000062881__50">Treatment Option Overview for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</a>
|
|
</b>
|
|
</p><p id="CDR0000062881__735">Revised <a href="/books/NBK65849/table/CDR0000062881__702/?report=objectonly" target="object" rid-ob="figobCDR0000062881702">Table 6</a>, Treatment Options for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas.</p><p id="CDR0000062881__723">
|
|
<b>
|
|
<a href="#CDR0000062881__73">Treatment of Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome</a>
|
|
</b>
|
|
</p><p id="CDR0000062881__724">Added <a href="/books/NBK65849/?report=reader#CDR0000062881__699">text</a> to state that there are anecdotal reports of hyperprogression of T-cell malignancies following treatment with immune checkpoint inhibitors (cited Ratner et al. and Bennani et al. as references 53 and 54, respectively).</p><p id="CDR0000062881__725">
|
|
<b>
|
|
<a href="#CDR0000062881__102">Treatment of Recurrent Mycosis Fungoides and Sézary Syndrome</a>
|
|
</b>
|
|
</p><p id="CDR0000062881__726">Added <a href="/books/NBK65849/?report=reader#CDR0000062881__697">text</a> to state that mogamulizumab appeared to be especially effective in patients with blood involvement, such as those with Sézary syndrome.</p><p id="CDR0000062881__727">Added <a href="#CDR0000062881__715">text</a> to state that mogamulizumab is often avoided in patients scheduled to undergo allogeneic stem cell transplant, based on data from a Japanese study (cited Sugio et al. as reference 49).</p><p id="CDR0000062881__728">
|
|
<b>
|
|
<a href="#CDR0000062881__617">Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma</a>
|
|
</b>
|
|
</p><p id="CDR0000062881__729">This section was extensively revised.</p><p id="CDR0000062881__730">
|
|
<b>
|
|
<a href="#CDR0000062881__717">Treatment of Primary Cutaneous Gamma-Delta T-Cell Lymphoma</a>
|
|
</b>
|
|
</p><p id="CDR0000062881__731">Added this new section.</p><p id="CDR0000062881__732">
|
|
<b>
|
|
<a href="#CDR0000062881__719">Treatment of Primary Cutaneous Aggressive Epidermotropic CD8-Positive T-Cell Lymphoma</a>
|
|
</b>
|
|
</p><p id="CDR0000062881__733">Added this new section.</p><p id="CDR0000062881__disclaimerHP_3">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Adult Treatment Editorial Board</a>, which is
|
|
editorially independent of NCI. The summary reflects an independent review of
|
|
the literature and does not represent a policy statement of NCI or NIH. More
|
|
information about summary policies and the role of the PDQ Editorial Boards in
|
|
maintaining the PDQ summaries can be found on the <a href="#CDR0000062881__AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ® Cancer Information for Health Professionals</a> pages.
|
|
</p></div><div id="CDR0000062881__AboutThis_1"><h2 id="_CDR0000062881__AboutThis_1_">About This PDQ Summary</h2><div id="CDR0000062881__AboutThis_2"><h3>Purpose of This Summary</h3><p id="CDR0000062881__AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of mycosis fungoides and other cutaneous T-cell lymphomas. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</p></div><div id="CDR0000062881__AboutThis_4"><h3>Reviewers and Updates</h3><p id="CDR0000062881__AboutThis_5">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Adult Treatment Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="CDR0000062881__AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</p><ul id="CDR0000062881__AboutThis_6"><li class="half_rhythm"><div>be discussed at a meeting,</div></li><li class="half_rhythm"><div>be cited with text, or</div></li><li class="half_rhythm"><div>replace or update an existing article that is already cited.</div></li></ul><p id="CDR0000062881__AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.</p><p>The lead reviewers for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment are:</p><ul><li class="half_rhythm"><div>Eric J. Seifter, MD (Johns Hopkins University)</div></li><li class="half_rhythm"><div>Cole H. Sterling, MD (Johns Hopkins University)</div></li></ul><p id="CDR0000062881__AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></div><div id="CDR0000062881__AboutThis_10"><h3>Levels of Evidence</h3><p id="CDR0000062881__AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <a href="/books/n/pdqcis/CDR0000062796/?report=reader">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></div><div id="CDR0000062881__AboutThis_12"><h3>Permission to Use This Summary</h3><p id="CDR0000062881__AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</p><p id="CDR0000062881__AboutThis_14">The preferred citation for this PDQ summary is:</p><p id="CDR0000062881__AboutThis_15">PDQ® Adult Treatment Editorial Board. PDQ Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: <a href="https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq</a>. Accessed <MM/DD/YYYY>. [PMID: 26389288]</p><p id="CDR0000062881__AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Visuals Online</a>, a collection of over 2,000 scientific images.
|
|
</p></div><div id="CDR0000062881__AboutThis_17"><h3>Disclaimer</h3><p id="CDR0000062881__AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Managing Cancer Care</a> page.</p></div><div id="CDR0000062881__AboutThis_20"><h3>Contact Us</h3><p id="CDR0000062881__AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website’s <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>.</p></div></div></div></div><div class="fm-sec"><h2 id="_NBK65849_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><p class="contrib-group"><h4>Authors</h4><span itemprop="author">PDQ Adult Treatment Editorial Board</span>.</p><h3>Publication History</h3><p class="small">Published online: August 16, 2024.</p><h3>Version History</h3><ul class="simple-list" style="padding:0"><li><span class="bk_col_itm">NBK65849.16</span> August 16, 2024 (Displayed Version)</li><li><span class="bk_col_itm"><a href="/books/NBK65849.15/?report=reader">NBK65849.15</a></span> May 23, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK65849.14/?report=reader">NBK65849.14</a></span> June 27, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK65849.13/?report=reader">NBK65849.13</a></span> February 24, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK65849.12/?report=reader">NBK65849.12</a></span> February 28, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65849.11/?report=reader">NBK65849.11</a></span> January 14, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65849.10/?report=reader">NBK65849.10</a></span> September 20, 2019</li><li><span class="bk_col_itm"><a href="/books/NBK65849.9/?report=reader">NBK65849.9</a></span> May 17, 2019</li><li><span class="bk_col_itm"><a href="/books/NBK65849.8/?report=reader">NBK65849.8</a></span> July 5, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK65849.7/?report=reader">NBK65849.7</a></span> May 4, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK65849.6/?report=reader">NBK65849.6</a></span> March 28, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK65849.5/?report=reader">NBK65849.5</a></span> July 12, 2017</li><li><span class="bk_col_itm"><a href="/books/NBK65849.4/?report=reader">NBK65849.4</a></span> March 3, 2016</li><li><span class="bk_col_itm"><a href="/books/NBK65849.3/?report=reader">NBK65849.3</a></span> January 29, 2016</li><li><span class="bk_col_itm"><a href="/books/NBK65849.2/?report=reader">NBK65849.2</a></span> December 23, 2015</li><li><span class="bk_col_itm"><a href="/books/NBK65849.1/?report=reader">NBK65849.1</a></span> August 6, 2015</li></ul><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.cancer.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Cancer Institute (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>PDQ Adult Treatment Editorial Board. Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®): Health Professional Version. 2024 Aug 16. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobCDR0000062881584"><div id="CDR0000062881__584" class="table"><h3><span class="title">Table 1. Histopathological Staging of Lymph Nodes in Cutaneous T-Cell Lymphoma<sup>a</sup></span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65849/table/CDR0000062881__584/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062881__584_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">EORTC Classification</th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Dutch System</th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">NCI-VA Classification</th></tr></thead><tbody><tr><td colspan="1" rowspan="3" style="vertical-align:top;">N1</td><td colspan="1" rowspan="3" style="vertical-align:top;">Grade 1: DL</td><td colspan="1" rowspan="1" style="vertical-align:top;">LN0: No atypical lymphocytes.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">LN1: Occasional and isolated atypical lymphocytes (not arranged in clusters).</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">LN2: Many atypical lymphocytes or lymphocytes in 3-6‒cell clusters.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N2</td><td colspan="1" rowspan="1" style="vertical-align:top;">Grade 2: DL; early involvement by mycosis fungoides (presence of cerebriform nuclei <7.5 µm [micrometer]).</td><td colspan="1" rowspan="1" style="vertical-align:top;">LN3: Aggregates of atypical lymphocytes; nodal architecture preserved.</td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">N3</td><td colspan="1" rowspan="1" style="vertical-align:top;">Grade 3: Partial effacement of lymph node architecture; many atypical cerebriform mononuclear cells.</td><td colspan="1" rowspan="2" style="vertical-align:top;">LN4: Partial/complete effacement of nodal architecture by atypical lymphocytes or frankly neoplastic cells.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Grade 4: Complete effacement.</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">DL = dermatopathic lymphadenopathy; EORTC = European Organisation for Research and Treatment of Cancer; LN = lymph nodes; N = regional lymph node; NCI = National Cancer Institute; VA = U.S. Department of Veterans Affairs.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>a</sup>Reprinted with permission from AJCC: Primary Cutaneous Lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 967–72.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobCDR0000062881580"><div id="CDR0000062881__580" class="table"><h3><span class="title">Table 2. Definitions of TNM Stages IA and IB<sup>a</sup></span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062881__580_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Stage </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">TNM </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Description </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">B </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Peripheral Blood Involvement Criteria</th></tr></thead><tbody><tr><td colspan="1" rowspan="7" style="vertical-align:top;">IA </td><td colspan="1" rowspan="7" style="vertical-align:top;">T1, N0, M0 </td><td colspan="1" rowspan="1" style="vertical-align:top;">T1 = Limited patches,<sup>b</sup> papules, and/or plaques<sup>c</sup> covering <10% of the skin surface. </td><td colspan="1" rowspan="7" style="vertical-align:top;">B0,1</td><td colspan="1" rowspan="2" style="vertical-align:top;">B0 = Absence of significant blood involvement: ≤5% of peripheral blood lymphocytes are atypical (Sézary) cells.<sup>d</sup></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–T1a = T1a (patch only).</td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">–T1b = T1b (plaque ± patch).</td><td colspan="1" rowspan="1" style="vertical-align:top;">–B0a = Clone negative<sup>e</sup></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–B0b = Clone positive<sup>e</sup></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N0 = No clinically abnormal peripheral lymph nodes;<sup>f</sup> biopsy not required.</td><td colspan="1" rowspan="1" style="vertical-align:top;">B1 = Low blood tumor burden: >5% of peripheral blood lymphocytes are atypical (Sézary) cells, but does not meet the criteria of B2.</td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">M0 = No visceral organ involvement.</td><td colspan="1" rowspan="1" style="vertical-align:top;">–B1a = Clone negative<sup>e</sup></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–B1b = Clone positive<sup>e</sup></td></tr><tr><td colspan="1" rowspan="5" style="vertical-align:top;">IB</td><td colspan="1" rowspan="5" style="vertical-align:top;">T2, N0, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">T2 = Patches, papules, or plaques covering ≥10% of the skin surface.</td><td colspan="1" rowspan="5" style="vertical-align:top;">B0,1</td><td colspan="1" rowspan="5" style="vertical-align:top;">See B0, B1 descriptions above in this table, Stage IA.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–T2a = T2a (patch only).</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–T2b = T2b (plaque ± patch).</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N0 = No clinically abnormal peripheral lymph nodes;<sup>f</sup> biopsy not required.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No visceral organ involvement.</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">T = primary tumor; N = regional lymph node; M = distant metastasis; B = peripheral blood involvement.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>a</sup>Reprinted with permission from AJCC: Primary Cutaneous Lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 967–72.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The explanations for superscripts b through f are at the end of <a href="/books/NBK65849/table/CDR0000062881__583/?report=objectonly" target="object" rid-ob="figobCDR0000062881583">Table 5</a>.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobCDR0000062881581"><div id="CDR0000062881__581" class="table"><h3><span class="title">Table 3. Definitions of TNM Stages IIA and IIB<sup>a</sup></span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65849/table/CDR0000062881__581/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062881__581_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Stage </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">TNM </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Description </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">B </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Peripheral Blood Involvement Criteria</th></tr></thead><tbody><tr><td colspan="1" rowspan="8" style="vertical-align:top;">IIA</td><td colspan="1" rowspan="8" style="vertical-align:top;">T1,2; N1,2; M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">See T1–2 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table 2</a>, Stages IA, IB.</td><td colspan="1" rowspan="8" style="vertical-align:top;">B0,1</td><td colspan="1" rowspan="8" style="vertical-align:top;">See B0, B1 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table 2</a>, Stage IA.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N1 = Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0–2.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–N1a = Clone negative.<sup>e</sup></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–N1b = Clone positive.<sup>e</sup></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N2 = Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–N2a = Clone negative.<sup>e</sup></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–N2b = Clone positive.<sup>e</sup></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No visceral organ involvement.</td></tr><tr><td colspan="1" rowspan="6" style="vertical-align:top;">IIB</td><td colspan="1" rowspan="6" style="vertical-align:top;">T3, N0–2, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">T3 = One or more tumors<sup>g</sup> (≥1 cm in diameter).</td><td colspan="1" rowspan="6" style="vertical-align:top;">B0,1</td><td colspan="1" rowspan="6" style="vertical-align:top;">See B0, B1 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table 2</a>, Stage IA.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–T3a = Multiple lesions involving 2 noncontiguous body regions.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–T3b = Multiple lesions involving ≥3 body regions.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N0 = No clinically abnormal peripheral lymph nodes;<sup>f</sup> biopsy not required.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">See N1–2 descriptions above in this table, Stage IIA</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No visceral organ involvement.</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">T = primary tumor; N = regional lymph node; M = distant metastasis; B = peripheral blood involvement; LN = lymph nodes; NCI = National Cancer Institute.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>a</sup>Reprinted with permission from AJCC: Primary Cutaneous Lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 967–72.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The explanations for superscripts e through g are at the end of <a href="/books/NBK65849/table/CDR0000062881__583/?report=objectonly" target="object" rid-ob="figobCDR0000062881583">Table 5</a>.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobCDR0000062881582"><div id="CDR0000062881__582" class="table"><h3><span class="title">Table 4. Definitions of TNM Stages III, IIIA, and IIIB<sup>a</sup></span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65849/table/CDR0000062881__582/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062881__582_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Stage </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">TNM </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Description </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">B </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Peripheral Blood Involvement Criteria</th></tr></thead><tbody><tr><td colspan="1" rowspan="3" style="vertical-align:top;">III</td><td colspan="1" rowspan="3" style="vertical-align:top;">T4, N0–2, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">T4 = Confluence of erythema covering ≥80% of body surface area.</td><td colspan="1" rowspan="3" style="vertical-align:top;">B0,1</td><td colspan="1" rowspan="3" style="vertical-align:top;">See B0, B1 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table 2</a>, Stage IA.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">See N0–2 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__581/?report=objectonly" target="object" rid-ob="figobCDR0000062881581">Table 3</a>, Stages IIA, IIB.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No visceral organ involvement.</td></tr><tr><td colspan="1" rowspan="3" style="vertical-align:top;">IIIA</td><td colspan="1" rowspan="3" style="vertical-align:top;">T4, N0–2, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">T4 = Confluence of erythema covering ≥80% of body surface area.</td><td colspan="1" rowspan="3" style="vertical-align:top;">B0</td><td colspan="1" rowspan="3" style="vertical-align:top;">See B0 description above in <a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table 2</a>, Stage IA.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">See N0–2 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__581/?report=objectonly" target="object" rid-ob="figobCDR0000062881581">Table 3</a>, Stages IIA, IIB.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No visceral organ involvement.</td></tr><tr><td colspan="1" rowspan="3" style="vertical-align:top;">IIIB</td><td colspan="1" rowspan="3" style="vertical-align:top;">T4, N0–2, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">T4 = Confluence of erythema covering ≥80% of body surface area.</td><td colspan="1" rowspan="3" style="vertical-align:top;">B1</td><td colspan="1" rowspan="3" style="vertical-align:top;">See B1 description above in <a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table 2</a>, Stage IA.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">See N0–2 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__581/?report=objectonly" target="object" rid-ob="figobCDR0000062881581">Table 3</a>, Stages IIA, IIB.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No visceral organ involvement.</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">T = primary tumor; N = regional lymph node; M = distant metastasis; B = peripheral blood involvement.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>a</sup>Reprinted with permission from AJCC: Primary Cutaneous Lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 967–72.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobCDR0000062881583"><div id="CDR0000062881__583" class="table"><h3><span class="title">Table 5. Definitions of TNM Stages IVA1, IVA2, and IVB<sup>a</sup></span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65849/table/CDR0000062881__583/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062881__583_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Stage </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">TNM </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Description </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">B </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Peripheral Blood Involvement Criteria</th></tr></thead><tbody><tr><td colspan="1" rowspan="7" style="vertical-align:top;">IVA1</td><td colspan="1" rowspan="7" style="vertical-align:top;">T1–4, N0–2, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">See T1‒2 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table 2</a>, Stages IA, IB.</td><td colspan="1" rowspan="7" style="vertical-align:top;">B2</td><td colspan="1" rowspan="7" style="vertical-align:top;">B2 = High blood tumor burden: ≥1,000 mcg/L
|
|
Sézary cells<sup>d</sup> or >40% CD4+/CD7- or increased >30% CD4+/CD26- cells with positive clone.<sup>e</sup>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">T3 = One or more tumors<sup>g</sup> (≥1 cm in diameter).</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–T3a = Multiple lesions involving 2 noncontiguous body regions.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–T3b = Multiple lesions involving ≥3 body regions.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">T4 = Confluence of erythema covering ≥80% of body surface area.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">See N0–2 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__581/?report=objectonly" target="object" rid-ob="figobCDR0000062881581">Table 3</a>, Stages IIA, IIB.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No visceral organ involvement.</td></tr><tr><td colspan="1" rowspan="3" style="vertical-align:top;">IVA2 </td><td colspan="1" rowspan="3" style="vertical-align:top;">T1–4, N3, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">See T1‒2 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table 2</a>, Stages IA, IB and see T3–4 descriptions above in this table, Stage IVA1.</td><td colspan="1" rowspan="3" style="vertical-align:top;">B0–2</td><td colspan="1" rowspan="3" style="vertical-align:top;">See B0, B1 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table 2</a>, Stage IA and see B2 description above in this table, Stage IVA1.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N3 = Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3–4 or NCI LN4; clone positive or negative.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No visceral organ involvement.</td></tr><tr><td colspan="1" rowspan="4" style="vertical-align:top;">IVB</td><td colspan="1" rowspan="4" style="vertical-align:top;">T1–4, N0–3, M1</td><td colspan="1" rowspan="1" style="vertical-align:top;">See T1‒2 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table 2</a>, Stages IA, IB and see T3–4 descriptions above in this table, Stage IVA1.</td><td colspan="1" rowspan="4" style="vertical-align:top;">B0–2</td><td colspan="1" rowspan="4" style="vertical-align:top;">See B0, B1 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__580/?report=objectonly" target="object" rid-ob="figobCDR0000062881580">Table 2</a>, Stage IA and see B2 description above in this table, Stage IVA1.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">See N0–2 descriptions above in <a href="/books/NBK65849/table/CDR0000062881__581/?report=objectonly" target="object" rid-ob="figobCDR0000062881581">Table 3</a>, Stages IIA, IIB.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N3 = Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3–4 or NCI LN4; clone positive or negative.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M1 = Visceral involvement (must have pathology confirmation,<sup>h</sup> and organ involved should be specified).</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">T = primary tumor; N = regional lymph node; M = distant metastasis; B = peripheral blood involvement; LN = lymph nodes; NCI = National Cancer Institute.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>a</sup>Reprinted with permission from AJCC: Primary Cutaneous Lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 967–72.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>b</sup>For skin, <b>patch</b> indicates any size skin lesion without significant elevation or induration. Presence/absence of hypo- or hyperpigmentation, scale, crusting, and/or poikiloderma should be noted.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>c</sup>For skin, <b>plaque</b> indicates any size skin lesion that is elevated or indurated. Presence/absence of scale, crusting, and/or poikiloderma should be noted. Histological features such as folliculotropism, large cell transformation (>25% large cells) and CD30 positivity or negativity, as well as clinical features such as ulceration, are important to document.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>d</sup>For blood, Sézary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. If Sézary cells cannot be used to determine tumor burden for B2, then one of the following modified ISCL criteria, along with a positive clonal rearrangement of the T-cell receptor (TCR), may be used instead: (1) expanded CD4+ or CD3+ cells with a CD4/CD8 ratio of >10, or (2) expanded CD4+ cells with abnormal immunophenotype, including loss of CD7 (>40%) or CD26 (>30%).</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>e</sup>A T-cell clone is defined by polymerase chain reaction or Southern blot analysis of the TCR gene.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>f</sup>For node, <b>abnormal peripheral lymph node(s)</b> indicates any palpable peripheral node that on physical examination is firm, irregular, clustered, fixed or ≥1.5 cm in diameter. Node groups examined on physical examination include cervical, supraclavicular, epitrochlear, axillary, and inguinal. Central nodes, which generally are not amenable to pathological assessment, currently are not considered in the nodal classification unless used to establish N3 histopathologically.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>g</sup>For skin, <b>tumor</b> indicates at least one 1-cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. Note the total number of lesions, total volume of lesions, largest size lesion, and region of body involved. Also note whether there is histological evidence of large cell transformation. Phenotyping for CD30 is encouraged.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><sup>h</sup>For viscera, spleen and liver may be diagnosed by imaging criteria.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobCDR0000062881702"><div id="CDR0000062881__702" class="table"><h3><span class="title">Table 6. Treatment Options for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65849/table/CDR0000062881__702/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062881__702_lrgtbl__"><table class="no_top_margin"><thead><tr><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Stage (<a href="#CDR0000062881__10">TNM Definitions</a>)</th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Treatment Options</th></tr></thead><tbody><tr><td colspan="1" rowspan="6" style="vertical-align:top;">Stage I and Stage II Mycosis Fungoides</td><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__620">Photodynamic therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__622">Radiation therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__624">Biological therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__626">Chemotherapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__628">Other drug therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__630">Targeted therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="7" style="vertical-align:top;">Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome</td><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__648">Photodynamic therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__650">Radiation therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__652">Biological therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__654">Chemotherapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__656">Other drug therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__658">Targeted therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__660">Checkpoint inhibitors</a>
|
|
</td></tr><tr><td colspan="1" rowspan="7" style="vertical-align:top;">Recurrent Mycosis Fungoides and Sézary Syndrome</td><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__666">Radiation therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__668">Photodynamic therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__670">Chemotherapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__672">Other drug therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__674">Biological therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__676">Allogeneic stem cell transplant</a>
|
|
</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">
|
|
<a href="#CDR0000062881__678">Targeted therapy</a>
|
|
</td></tr><tr><td colspan="1" rowspan="3" style="vertical-align:top;">Primary Cutaneous Anaplastic Large Cell Lymphoma</td><td colspan="1" rowspan="1" style="vertical-align:top;">Radiation therapy</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Targeted therapy</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Chemotherapy</td></tr><tr><td colspan="1" rowspan="4" style="vertical-align:top;">Subcutaneous Panniculitis-Like T-Cell Lymphoma</td><td colspan="1" rowspan="1" style="vertical-align:top;">Immunosuppression</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Chemotherapy</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Targeted therapy</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Allogeneic stem cell transplant</td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">Primary Cutaneous Gamma Delta T-Cell Lymphoma</td><td colspan="1" rowspan="1" style="vertical-align:top;">Chemotherapy</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Allogeneic stem cell transplant</td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">Primary Cutaneous Aggressive Epidermotropic CD8-Positive T-Cell Lymphoma</td><td colspan="1" rowspan="1" style="vertical-align:top;">Chemotherapy</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Allogeneic stem cell transplant</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|